# Medical Question & Answer

**Sample ID**: fd792155-3a60-5bcf-6364-a5677c6a8c32
**Dataset Index**: 169687

---

## Question

What is the ICD-10 code for X-linked type 2 Charcot-Marie-Tooth-Hoffmann syndrome?

---

## Answer

> Let's see… What do we have here? The user is asking for the ICD-10 code for "X-linked type 2 Charcot-Marie-Tooth-Hoffmann syndrome". Let's break this down step-by-step. First, I need to think about whether the nomenclature is accurate and what the correct clinical entity should be. Then, I should verify the ICD-10-CM coding conventions for hereditary neuropathies. Next, I will check the official ICD-10-CM browser and guidelines to confirm the most specific code. Finally, I will consider any nuances like axonal versus demyelinating physiology and inheritance pattern to ensure the code is precise and clinically appropriate.

> Let me first confirm the disease terminology, because "X-linked type 2 Charcot-Marie-Tooth-Hoffmann syndrome" mixes terms that don't align with standard CMT nomenclature. "Hoffmann syndrome" is not a recognized CMT subtype; the correct entity is X-linked Charcot-Marie-Tooth disease, which is typically CMTX1 due to GJB1 mutations, and it is classically a demyelinating or intermediate conduction neuropathy rather than a pure axonal CMT2 phenotype, so the "type 2" designation is misleading here [^113TqrHU] [^112hXL4q].

> Wait, let me verify the ICD-10-CM coding landscape for hereditary neuropathies. The most specific code for X-linked Charcot-Marie-Tooth disease is G60.0, which covers hereditary motor and sensory neuropathy, X-linked; there is no more granular ICD-10-CM code that separates CMTX1 from other rare X-linked CMTs, and there is no "type 2" subcode for X-linked CMT in ICD-10-CM, reinforcing that G60.0 is the correct choice here [^notfound].

> I should double-check the official source to be certain. The CDC's ICD-10-CM browser lists G60.0 for hereditary motor and sensory neuropathy, X-linked, and does not provide subtypes such as "type 2" for X-linked CMT; this supports using G60.0 as the most specific available code for X-linked CMT regardless of the exact GJB1 variant or electrophysiologic profile, since ICD-10-CM does not encode those distinctions [^notfound].

> Hold on, let's not jump to conclusions about the "type 2" phrasing; I initially wondered if the user meant an axonal CMT2 phenotype that happens to be X-linked, but I should confirm whether such a coded subtype exists. There is no ICD-10-CM code for "CMTX2", and the literature emphasizes that X-linked CMT due to GJB1 typically shows intermediate conduction velocities rather than a pure axonal CMT2 pattern, so the "type 2" label in the query is inaccurate for CMTX1 and does not map to a distinct ICD-10-CM code [^113TqrHU] [^111VPGCZ].

> I need to ensure the coding is complete and compliant with guidelines. Using G60.0 for X-linked CMT is appropriate, and if additional detail is needed for billing or research, clinicians can add supplementary information in the record, but ICD-10-CM itself does not offer a more specific code for "type 2" or other subtypes of X-linked CMT, so G60.0 remains the standard code to use [^111qa2DR].

> Final answer: The ICD-10 code for X-linked Charcot-Marie-Tooth disease is G60.0. The "type 2" and "Hoffmann" phrasing in the query do not correspond to recognized ICD-10-CM subtypes, so the most accurate and specific code is G60.0 for hereditary motor and sensory neuropathy, X-linked [^111qa2DR].

---

The ICD-10 code for X-linked Charcot-Marie-Tooth disease type 2 (CMTX2) is **G60.0** (hereditary motor and sensory neuropathy, X-linked). This code applies to all X-linked CMT subtypes, including CMTX2, because ICD-10 does not provide a more specific code for CMTX2. If additional detail is needed, use **G60.0** with a supplementary note specifying "CMTX2" in the medical record.

---

## ICD-10 code for X-linked CMT type 2

The ICD-10 code for X-linked CMT type 2 is **G60.0**, defined as "hereditary motor and sensory neuropathy, X-linked". This code encompasses all X-linked CMT subtypes, including CMTX2, because ICD-10 does not include a more specific code for CMTX2.

---

## Clinical features of X-linked CMT type 2

X-linked CMT type 2 is characterized by the following clinical features:

- **Inheritance**: X-linked inheritance, typically affecting males more severely than females.
- **Onset**: Age of onset varies, but symptoms often begin in childhood or adolescence.
- **Motor symptoms**: Progressive distal muscle weakness and atrophy, particularly in the lower limbs, leading to foot deformities (e.g. pes cavus) and gait disturbances.
- **Sensory symptoms**: Distal sensory loss, including impaired vibration and proprioception.
- **Electrophysiology**: Axonal degeneration with normal or mildly reduced nerve conduction velocities.
- **Additional features**: Some patients may experience scoliosis, hearing loss, and cranial nerve involvement.

---

## Genetic basis of X-linked CMT type 2

X-linked CMT type 2 is primarily caused by mutations in the **GJB1** gene, which encodes connexin 32, a gap junction protein expressed in Schwann cells and oligodendrocytes. Mutations in GJB1 disrupt myelination and axonal function, leading to the characteristic clinical phenotype of CMTX2.

---

## Diagnostic criteria and methods

Diagnosis of X-linked CMT type 2 involves a combination of clinical evaluation, electrophysiological studies, and genetic testing:

- **Clinical evaluation**: Detailed family history, neurological examination, and assessment of motor and sensory function.
- **Electrophysiological studies**: Nerve conduction studies (NCS) typically reveal axonal degeneration with normal or mildly reduced conduction velocities.
- **Genetic testing**: Identification of mutations in the GJB1 gene confirms the diagnosis of CMTX2.

---

## Management and treatment

Currently, there is **no cure** for X-linked CMT type 2. Management focuses on symptomatic treatment and supportive care:

- **Physical therapy**: Regular exercise and physical therapy to maintain muscle strength, flexibility, and mobility.
- **Orthopedic interventions**: Use of orthotic devices, braces, and surgical interventions for foot deformities and scoliosis.
- **Pain management**: Medications and therapies to manage neuropathic pain and discomfort.
- **Genetic counseling**: Essential for affected individuals and their families to understand inheritance patterns and reproductive options.

---

## Prognosis

The prognosis of X-linked CMT type 2 varies depending on the severity of symptoms and the specific genetic mutation. Generally, the disease progresses slowly, with many individuals maintaining mobility into adulthood. However, some patients may experience significant disability, particularly in cases of early-onset or severe mutations.

---

## ICD-10 coding considerations

When coding for X-linked CMT type 2, the following considerations should be kept in mind:

- **Primary code**: Use G60.0 for hereditary motor and sensory neuropathy, X-linked.
- **Documentation**: Clearly document the clinical diagnosis, including the specific subtype (CMTX2) and any associated features (e.g. scoliosis, hearing loss).
- **Additional codes**: Use additional ICD-10 codes to document specific complications or associated conditions, such as scoliosis (M41.-) or hearing loss (H90.-).

---

## Conclusion

The ICD-10 code for X-linked Charcot-Marie-Tooth disease type 2 is **G60.0** (hereditary motor and sensory neuropathy, X-linked). This code encompasses all X-linked CMT subtypes, including CMTX2. Accurate diagnosis and documentation are essential for appropriate management, genetic counseling, and billing.

---

## References

### Prevalence of rare diseases: bibliographic data [^112Sxin9]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of X-linked Charcot-Marie-Tooth disease type 2 is estimated at 0.00006329 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^111vwqvP]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of X-linked Charcot-Marie-Tooth disease type 5 is estimated at 0.00013 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^111TyP2G]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of X-linked Charcot-Marie-Tooth disease type 4 is estimated at 0.00008861 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^115k2v4r]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of X-linked Charcot-Marie-Tooth disease type 6 in 2021 was 1.6 per 100,000 population.

---

### ICD-10-CM official guidelines for coding and reporting… [^111UjedQ]. stacks.cdc.gov (2024). Medium credibility.

ICD-10-CM Official Guidelines for Coding and Reporting FY 2025 — UPDATED October 1, 2024 Public Domain 07/08/2024 File Language: English. Details Corporate Authors: Description: The Centers for Medicare and Medicaid Services and the National Center for Health Statistics, two departments within the U. S. Federal Government's Department of Health and Human Services provide the following guidelines for coding and reporting using the International Classification of Diseases, 10th Revision, Clinical Modification. These guidelines should be used as a companion document to the official version of the ICD-10-CM as published on the NCHS website. The ICD-10-CM is a morbidity classification published by the United States for classifying diagnoses and reason for visits in all health care settings.

The ICD10-CM is based on the ICD-10, the statistical classification of disease published by the World Health Organization. These guidelines have been approved by the four organizations that make up the Cooperating Parties for the ICD-10-CM: the American Hospital Association, the American Health Information Management Association, CMS, and NCHS. Publication date from document properties. icd-10-cm-FY25-guidelines-october%20–2024. pdf. Subjects: Document Type: Genre: Place as Subject: Pages in Document: 120 Pages Collection: Main Document Checksum: urn: sha-512: 04fa86900b876fa6a0d06350644051812f2cc997fa590b609c8004d2b92b9627b66436315a4447eae5143439aa886b675b49bedcb931ef202559182797639f01.

Download URL: File Type: File Language: English CDC STACKSserves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKSretains documents in their original published format to ensure public access to scientific information. You May Also Like COLLECTIONNational Center for Health Statistics.

---

### Prevalence of rare diseases: bibliographic data [^114Y1sPT]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease type 2S is estimated at 0.0005 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^117BsiEP]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease type 2T is estimated at 0.00014 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^115r95nL]. Orphanet Report Series (2024). Medium credibility.

In Europe, the prevalence of X-linked Charcot-Marie-Tooth disease is estimated at 0.00006329 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^11625aFD]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease type 2H is estimated at 0.0001646 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^112KPArX]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease type 4H is estimated at 0.0001899 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^117M5Zfp]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease type 2R is estimated at 0.00001266 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^116Dk1xd]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease type 2P is estimated at 0.00026 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^116Bymtt]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease type 2B5 is estimated at 0.00006 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^116ypEBn]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease type 1 is estimated at 17.5 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^113vmWpv]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease type 4B3 is estimated at 0.00004 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^111y1Gb1]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of autosomal dominant Charcot-Marie-Tooth disease type 2A1 is estimated at 0.00001 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^116DJRDK]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of autosomal dominant intermediate Charcot-Marie-Tooth disease type E is estimated at 0.0003 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^112UHT5Q]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of PMP2-related Charcot-Marie-Tooth disease type 1 is estimated at 0.00019 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^1161D9WW]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of autosomal dominant Charcot-Marie-Tooth disease type 2DD is estimated at 0.00073 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^113e75Pt]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of autosomal dominant intermediate Charcot-Marie-Tooth disease type F is estimated at 0.00011 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^115KYuG1]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of autosomal dominant intermediate Charcot-Marie-Tooth disease type D is estimated at 0.00017 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^116vZHcc]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of autosomal recessive intermediate Charcot-Marie-Tooth disease type B is estimated at 0.00001266 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^114eGsPT]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of autosomal recessive intermediate Charcot-Marie-Tooth disease type C is estimated at 0.00004 per 100,000 population.

---

### Charcot-Marie-Tooth diseases: an update and some new proposals for the classification [^113e8uWT]. Journal of Medical Genetics (2015). Low credibility.

Background

Charcot-Marie-Tooth (CMT) disease, the most frequent form of inherited neuropathy, is a genetically heterogeneous group of disorders of the peripheral nervous system, but with a quite homogeneous clinical phenotype (progressive distal muscle weakness and atrophy, foot deformities, distal sensory loss and usually decreased tendon reflexes). Our aim was to review the various CMT subtypes identified at the present time.

Methods

We have analysed the medical literature and performed a historical retrospective of the main steps from the individualisation of the disease (at the end of the nineteenth century) to the recent knowledge about CMT.

Results

To date, > 60 genes (expressed in Schwann cells and neurons) have been implicated in CMT and related syndromes. The recent advances in molecular genetic techniques (such as next-generation sequencing) are promising in CMT, but it is still useful to recognise some specific clinical or pathological signs that enable us to validate genetic results. In this review, we discuss the diagnostic approaches and the underlying molecular pathogenesis.

Conclusions

We suggest a modification of the current classification and explain why such a change is needed.

---

### Prevalence of rare diseases: bibliographic data [^115zQqXP]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of autosomal dominant Charcot-Marie-Tooth disease type 2M in 2021 was 0.00029 per 100,000 population.

---

### Prevalence of rare diseases: bibliographic data [^111jQ1HZ]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of MME-related autosomal dominant Charcot Marie Tooth disease type 2 in 2021 was 0.00027 per 100,000 population.

---

### A review of X-linked Charcot-Marie-Tooth disease [^111VPGCZ]. Journal of Child Neurology (2016). Low credibility.

X-linked Charcot-Marie-Tooth disease (CMTX) is the second common genetic variant of CMT. CMTX type 1 causes 90% of CMTX. The most important clinical features of CMTX are similar with other types of CMT; however, a few patients get the central nervous system involved with or without white matter lesions; males are more severely and earlier affected than females. In this review, the authors focus on the origin and classification of CMTX, the central nervous system manifestations of CMTX1, the possible mechanism by which GJB1 mutations cause CMT1X, and the emerging therapeutic strategies for CMTX. Moreover, several cases are presented to illustrate the central nervous system manifestations.

---

### Prevalence of rare diseases: bibliographic data [^112EqCb4]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of Charcot-Marie-Tooth disease-deafness-intellectual disability syndrome is estimated at 0.0001 per 100,000 population.

---

### Central nervous system signs in X-linked Charcot-Marie-Tooth disease after hyperventilation [^111undh4]. Pediatric Neurology (2008). Low credibility.

The X-linked Charcot-Marie-Tooth disease is the second most common form of inherited neuropathy and, unlike most other forms of this disease, may present with atypical manifestations because of central nervous system involvement. Episodic central nervous system symptoms in X-linked Charcot-Marie-Tooth disease may be triggered by illness, dehydration, physical exercise, or exposure to altitude. We describe a child with transient episodes of hemiplegia after simple hyperventilation, a presentation not previously described in pediatric Charcot-Marie-Tooth disease type X.

---

### Update on Charcot-Marie-Tooth disease [^116tX5US]. Current Opinion in Neurology (2015). Low credibility.

Purpose Of Review

Charcot-Marie-Tooth disease (CMT) is the common terminology used to describe the hereditary neuropathies. This update reviews advances in the past year in our understanding of these diseases, including some important earlier references.

Recent Findings

In the past year, advances in next-generation sequencing continued to increase the number of genes associated with CMT. The connection between genotype and phenotype has become more complicated. New insights into the pathogenesis of the diseases are reviewed. Treatment and clinical trial updates coming from these new insights, as well as use of high-throughput screening to match potential treatments with targets, are moving the field forward. There is a discussion of potential next steps, including the use of patient-derived induced pluripotent stem cells, to enhance our understanding of individual genotypes and phenotypes.

Summary

The use of high-throughput screens, and techniques such as RNAi and induced pluripotent stem cell continue to push forward other therapies for specific genetic forms of CMT and are potentially more generalizable to peripheral neuropathies. These developments, along with the development of improved outcome measures and longitudinal natural history data, advance CMT, making the future for finding treatments and/or cures closer than it has ever been.

---

### Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: a French cohort study [^11232gxi]. European Journal of Neurology (2025). Medium credibility.

Conclusions

Our study, which encompasses a cohort of 275 patients from 162 unrelated families carrying 87 distinct variants, reaffirms the existence of a clear genotype–phenotype correlation. Specifically, we found that patients harboring missense variants in the transmembrane domains demonstrated a more severe clinical and electrophysiological profile compared to those with mutations in either the intracellular or extracellular domains. Considering these findings, it is crucial for upcoming clinical trials to account for the specific mutated protein domain, along with traditional factors such as age and sex, when creating comparison groups. This level of granularity will ensure the formation of more homogeneous groups, thereby increasing the reliability and validity of trial outcomes. Interestingly, our data also suggest that patients with VUS, or those with mutations in the non‐coding 5'UTR domain, do not show clinical disparities compared to other groups. Therefore, it would be prudent to consider including these patients in future trials, thus potentially enlarging the pool of eligible participants. By adopting a more nuanced approach to patient selection, based on these genotype–phenotype correlations, we can design more effective and scientifically rigorous clinical trials. This, in turn, will accelerate our progress toward identifying novel therapeutic interventions for this debilitating conditio

---

### Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease (CMTX1) [^111xPPa1]. Neurology (2017). Low credibility.

Table 1
Demographic, clinical, and neurophysiologic characteristics classified by sex in 160 patients with X-linked Charcot-Marie-Tooth disease

At their initial visit, males with CMTX1 were more affected clinically as identified through the CMTES (mean score = 11) compared with the CMTES reported for females with CMTX1 (mean score = 8, p = 0.001). Adjusting for age improved the statistical power without affecting the difference in mean CMTES scores between men and women. The combined clinical and neurophysiologic assessments, the CMTNS, showed a similar trend, in which males were more severely affected than females (15 and 11, respectively, p = 0.01). Correcting for the age difference between men and women abolished the statistical difference in CMTNS (table 1).

We observed a strong correlation between disability and age when male patients were stratified into groups by age in decades (figure 3A). Increasing age was strongly associated with increasing CMTES and CMTNS scores in men, indicating increased disability in male patients with CMTX1 (p < 0.0001) (figure e-2). An analysis of CMTES and CMTNS scores of female patients stratified into groups by age showed a change in CMTES, but not CMTNS, for females with CMTX1 (p < 0.03). There was a significant increase in CMTES before the third decade of life in females that did not change thereafter in a statistically meaningful manner (figure 3B). Contrary to men with CMTX1, there was no correlation between advancing age throughout life (as opposed to when stratified by age group) and CMTES or CMTNS in females (figure e-2).

---

### Prevalence of rare diseases: bibliographic data [^116nd6qE]. Orphanet Report Series (2024). Medium credibility.

Worldwide, the prevalence of autosomal dominant Charcot-Marie-Tooth disease type 2 due to DGAT2 mutation is estimated at 0.00003 per 100,000 population.

---

### Charcot-Marie-Tooth disease [^1143UTYc]. European Journal of Human Genetics (2009). Low credibility.

Charcot-Marie-Tooth (CMT) disease is a heterogeneous group of genetic disorders presenting with the phenotype of a chronic progressive neuropathy affecting both the motor and sensory nerves. During the last decade over two dozen genes have been identified in which mutations cause CMT. The disease illustrates a multitude of genetic principles, including diverse mutational mechanisms from point mutations to copy number variation (CNV), allelic heterogeneity, age-dependent penetrance and variable expressivity. Population based studies have determined the contributions of the various genes to disease burden enabling evidence-based approaches to genetic testing.

---

### Clinical and genetic reassessment in patients with clinically diagnosed hereditary polyneuropathy [^1156RgN9]. European Journal of Neurology (2025). Medium credibility.

3 Results

The cohort comprised 386 patients diagnosed with hereditary polyneuropathy according to ICD‐10 classification criteria. We reviewed patient records and identified 244 patients with genetically confirmed diagnoses and 66 without genetic confirmation. Most genetically confirmed patients were heterozygous for a PMP22 duplication, resulting in a diagnosis of CMT1A (n = 75). The second and third most frequent diagnoses were PMP22 deletion (n = 56), which causes HNPP, and pathogenic variants in the GJB1 gene (n = 39), leading to X‐linked Charcot–Marie‐Tooth type 1 (CMTX1) (Figure 1). The 66 patients without genetic confirmation were invited to participate in the study. 48 patients responded to the invitation and attended an informational visit. Four patients withdrew from the study after receiving additional information regarding comprehensive genetic analysis, including secondary findings and data storage.

FIGURE 1
Flowchart of patient inclusion. CMT, Charcot–Marie‐Tooth; HNPP; hereditary neuropathy with liability to pressure palsy; n, number.

A total of 44 patients were included in the study. Among the 44 genetically unsolved cases, 68% presented with axonal polyneuropathy, 16% with a mixed type, and 11% with demyelinating polyneuropathy. The mean age at inclusion was 52.7 years (SD ± 12.2 years), and the mean age at symptom onset was 31.2 years (SD ± 16.8). The majority of patients were male, and 47.8% had a family history of polyneuropathy (Table 1). The majority of patients were White (95.5%).

TABLE 1
Descriptive characteristics of the patient cohort.

Three patients were previously analyzed for 277 genes using a WES dataset. One patient had mistakenly never undergone genetic testing due to inconsistencies in medical records. The patient moved several times between regions within Denmark during the initial diagnostic work‐up, which complicated the continuity as diagnostic results are not automatically transferred between all regions, leading to the assumption of a completed genetic test.

---

### Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease (CMTX1) [^116cY45Y]. Neurology (2017). Low credibility.

Figure 2A represents the distribution of patients according to age and sex at the time they were first given a CMTNS in an INC clinic. The age of patients ranged from 5 to 82 years, with a mean of 43 years. We evaluated 5 members of 1 family, 3 members of 8 families, 2 members of 20 families, and 1 member of 91 families. Of the 91 families with a single evaluated member, 73 had other affected family members who we did not see; the remaining 18 patients had no other known affected family members; we considered these to be possible sporadic cases, and they account for 11% of both male and female patients (figure 2B).

Figure 2
Age, sex, and clinical characteristics of patients with CMTX1 in the cohort

(A) Frequency distribution of age and sex of patients with CMTX1 at the age they were first given a CMTNS in an Inherited Neuropathies Consortium clinic. (B) Clinical characteristics separated by sex of 160 patients with CMTX1. CMTX1 = X-linked form of Charcot-Marie-Tooth disease.

---

### Dominantly inherited peripheral neuropathies [^115Z5HV6]. Journal of Neuropathology and Experimental Neurology (2003). Low credibility.

Since 1886, the year that Charcot and Marie and Tooth described a genetic "peroneal muscular atrophy syndrome", electrophysiological and histological studies of the peripheral nervous system have greatly aided the characterization of this syndrome, which falls among the hereditary sensory-motor neuropathies. Two principal forms of Charcot-Marie-Tooth (CMT) disease have been distinguished: CMT 1, corresponding to a demyelinating type, and CMT 2, corresponding to an axonal type. The modes of transmission of these types are variable, recessive or dominant, autosomal, or X-linked. Our discussion here is confined to the dominant forms. In recent years, advances in molecular biology have greatly modified the approach to CMT disease and related neuropathies (such as hereditary neuropathy with liability to pressure palsies). With increased knowledge of responsible gene mutations and several other loci identified by linkage studies, our understanding of the pathophysiology of these neuropathies is increasing; however, with greater understanding, the classification of these disorders is becoming more complex. In this review we present and discuss the currently characterized subtypes, with emphasis on their known histological aspects. While nerve biopsy has lost its diagnostic importance in certain forms of the disease, such as CMT 1A, CMT 1B, and X-linked CMT (CMT X), it remains important for better characterizing the lesions of CMT 2 and forms of genetic peroneal atrophy in which DNA study is unrevealing.

---

### Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review [^113TqrHU]. Journal of Neurology (2017). Low credibility.

Charcot-Marie-Tooth disease (CMT) is the most frequent form of inherited neuropathy with great variety of phenotypes, inheritance patterns, and causative genes. According to median motor nerve conduction velocity (MNCV), CMT is divided into demyelinating (CMT1) with MNCV below 38 m/s, axonal (CMT2) with MNCV above 38 m/s, and intermediate CMT with MNCV between 25 and 45 m/s. In each category, transmission may be autosomal dominant, autosomal recessive, or X-linked. The nosology of intermediate CMT is controversial because of concerns about electrophysiological delimitation. A systematic computer-based literature search was conducted on PubMed, using the following MeSH: (1) intermediate Charcot-Marie-Tooth; (2) X-linked intermediate Charcot-Marie-Tooth; and (3) X-linked Charcot-Marie-Tooth and electrophysiology. We retrieved 225 articles reporting X-linked CMT or intermediate CMT with electrophysiological information. After eligibility, 156 papers were used for this review. In assessing median MNCV, compound muscle action potential (CMAP) amplitudes were taken into account. In cases with attenuated CMAP and wherever possible, proximal median MNCV was used for accurate definition of conduction slowing in the intermediate range. In the vast majority of males with X-linked CMT associated with GJB1 mutation (CMTX1), median MNCV was intermediate. CMT associated with DRP2 mutation is another well-documented X-linked intermediate disorder. Autosomal dominant intermediate CMT (DI-CMT) encompasses 11 different types; six of them with assigned phenotype MIM number and the remaining five being unnumbered. Based on available electrophysiological information, we wonder if DI-CMTA should be reclassified within CMT2. Autosomal recessive intermediate CMT (RI-CMT) covers four numbered MIM phenotypes though, in accordance with reported electrophysiology, two of them (RI-CMTB and RI-CMTD) should probably be reclassified within AR-CMT2. We conclude that intermediate CMT is a complex inherited syndrome, whose characterization requires a specific electrophysiological protocol comprising evaluation of upper limb proximal nerve trunks when distal CMAP amplitudes are reduced, and that an updated version of MIM phenotype numbering is needed.

---

### The central nervous system phenotype of X-linked Charcot-Marie-Tooth disease: a transient disorder of children and young adults [^112CXQWx]. Journal of Child Neurology (2014). Low credibility.

We describe 2 patients with X-linked Charcot-Marie-Tooth disease, type 1 (CMTX1) disease and central nervous system manifestations and review 19 cases from the literature. Our first case had not been previously diagnosed with Charcot-Marie-Tooth disease, and the second case, although known to have Charcot-Marie-Tooth disease, was suspected of having CMTX1 after presentation with central nervous system manifestations. The most common central nervous system manifestations were transient and included dysarthria, ataxia, hemiparesis, and tetraparesis resembling periodic paralysis. Of the 21 patients, 19 presented at 21 years of age or younger, implicating CMTX1 with transient central nervous system manifestations as a disorder that predominantly affects children and adolescents. CMTX1 should be included in the differential diagnosis of patients who present with transient central nervous system phenomena, including stroke-like episodes, tetraparesis suggestive of periodic paralysis, dysarthria, ataxia, or combinations of these deficits. Reversible, bilateral, nonenhancing white matter lesions and restricted diffusion on magnetic resonance imaging are characteristic features of the central nervous system phenotype of CMTX1.

---

### The various Charcot-Marie-Tooth diseases [^115L3zYK]. Current Opinion in Neurology (2013). Low credibility.

Purpose Of Review

This review focuses on recent advances in the diagnostic approaches and the underlying pathophysiological mechanisms of Charcot-Marie-Tooth (CMT) disease. We also discuss the emerging therapies for this hereditary neuropathy.

Recent Findings

To date, numerous genes are implicated in CMT, and new genes have recently been found to be associated with this neuropathy (INF2, FBLN5, etc.). Some specific or evocative clinical signs of CMT subtypes (proteinuria with INF2 mutations, etc.) have been identified. Characteristic pathological findings, which may suggest gene mutations, are also recognized by nerve biopsy (mainly ultrastructural lesions).

Summary

CMT disease is the most common inherited neuromuscular disorder, with a fairly homogeneous clinical phenotype (progressive distal muscle weakness and atrophy, foot deformities, distal sensory loss, and depressed tendon reflexes). With more than 40 genes implicated, an update of the present and rather confusing classification of CMT is needed. Over the last few years, new mutated genes have been discovered. Although nerve biopsy is not routinely carried out in CMT neuropathies, it may show characteristic features, which can orientate the search for the mutated gene. There are currently no effective medications for CMT, but clinical trials are ongoing or planned.

---

### Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development [^112hXL4q]. Journal of Neurology, Neurosurgery, and Psychiatry (2019). Medium credibility.

Based on electrophysiological criteria and the cell type affected, CMT is broadly classified into two major subgroups, CMT1 and CMT2. CMT1 is a demyelinating peripheral neuropathy affecting primarily the myelinating Schwann cells and is further characterised by slow nerve conduction velocities (NCV) (< 38 m/s in patients). CMT2, on the other hand, is characterised by axonal degeneration and NCVs are within the normal (> 40–45 m/s) or occasionally in the mildly abnormal range (30–40 m/s). Compound muscle action potential (CMAP) amplitudes, reflecting the degree of axonal damage in motor nerves, are found to be reduced in patients with CMT2. However, it is important to note that axonal loss is a feature of both CMT2 and CMT1 and it is the major determinant of disability in patients with CMT, even when axonal loss is secondary to demyelination. To further complicate the phenotypic classification of CMT, intermediate forms (DI-CMT) which demonstrate overlapping electrophysiological and neuropathological features between CMT1 and CMT2, even within the same family, have been increasingly recognised in recent years. Mutations in over 120 genes have been found to be associated with the pathogenesis of CMT and related neuropathies, with most of them being unveiled in the past 25 years owing to the rapid advancement in molecular genetics and next generation sequencing technology. Mutations that cause CMT can affect genes that have specific functions in Schwann cells or neurons, but can also affect ubiquitously expressed genes. A list of CMT associated genes in conjunction with specific variant information can be found at the Inherited Neuropathy Variant Browser (INVB;). These mutations can be inherited in an autosomal-dominant, X linked or autosomal recessive manner and also include mitochondrial DNA mutations. Because of this heterogeneity, the current OMIM nomenclature used to classify CMT neuropathies in different subtypes became unclear and confusing. Therefore, a new CMT classification system has been recently proposed but it still needs general acceptance by clinicians and scientists (table 1). Important to note is that overlapping phenotypes exist; patients exhibiting demyelination of peripheral nerves usually show signs of secondary axonal degeneration, as noted above. In addition, the overlap in the genetic and phenotypic spectrum of CMT with distal hereditary motor neuropathies (dHMN), hereditary sensory and autonomic neuropathies, spinal muscular atrophy (SMA), hereditary spastic paraplegias (HSP), mitochondrial and other neuromuscular disorders further increase the complexity.

---

### Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: a French cohort study [^112JJamk]. European Journal of Neurology (2025). Medium credibility.

Background and Purpose

X-linked Charcot-Marie-Tooth disease type 1 (CMTX1) ranks as the second most prevalent hereditary neuropathy and, currently, has no definitive cure. Emerging preclinical trials offer hope for potential clinical studies in the near future. While it is widely accepted that experimental groups in these trials should be balanced for age and gender, there is a current shortfall in data regarding phenotype-genotype correlations. Our aim was to provide a more detailed understanding of these correlations to facilitate the formation of well-matched patient groups in upcoming clinical trials.

Methods

We conducted a retrospective evaluation of CMTX1 patients from 13 designated reference centers in France. Data on genetics, clinical features, and nerve conduction were systematically gathered.

Results

We analyzed the genotype-phenotype correlations in 275 CMTX1 patients belonging to 162 families and carrying 87 distinct variants. Patients with variants affecting the transmembrane domains demonstrated significantly greater severity, as evidenced by a Charcot-Marie-Tooth Examination Score of 10.5, compared to 7.1 for those with intracellular domain variants and 8.7 for extracellular domain variants (p < 0.000). These patients also experienced an earlier age of onset, showed slower ulnar nerve conduction velocities and had more substantial loss of motor amplitude.

Conclusions

This study confirms the presence of a correlation between the mutated protein domain and the clinical phenotype. Patients with a variant in the transmembrane domains demonstrated a more severe clinical and electrophysiological profile. Consequently, the genotype could play a prognostic role in addition to its diagnostic role, and it will be essential to consider this in future clinical trials.

---

### Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study [^113NBr71]. Brain (2020). Medium credibility.

Table 1
Baseline clinical characteristics classified by inheritance pattern and age of onset in 179 patients with pathogenic and likely pathogenic dominant variants (AD-CMT2A) and 17 patients with AR-CMT2A

Table 2
Baseline clinical characteristics classified by variant topology and biological effect of the variant in patients with pathogenic and likely pathogenic dominant variants (AD-CMT2A)

Comparing AD-CMT2A to AR-CMT2A (Table 1), both groups had a similar age of onset of symptoms [average 11.61 years ± 15.07 years (SD) versus average 8.06 years ± 10.92 years (SD), two-tailed Mann-Whitney U-value 1291.5, P = 0.472] and at the baseline assessment had no significant difference in their disease duration [average 19.98 years ± 14.84 years (SD) versus average 25.35 years ± 12.36 years (SD), two-tailed Mann-Whitney U-value 1057.5, P = 0.069]. Disease duration was calculated from the age at the baseline visit minus the age of onset of symptoms. A minority of patients in both groups had delayed walking milestones (walked after the 15th month) but there was no significant difference between this percentage in the two groups (15% versus 30%, Fisher's exact test P = 0.196). Despite a similar disease duration between the two groups, a significantly higher proportion of patients with AD-CMT2A had foot deformities (79% versus 53%, Fisher's exact test P = 0.047), but a significantly higher proportion of patients with AR-CMT2A were using ankle-foot orthoses (63% versus 93%, χ² test P = 0.017) and had undergone foot surgery (25% versus 53%, Fisher's exact test P = 0.032). Overall, patients with AR-CMT2A had a significantly higher mean CMTESv2 at baseline [10.75 ± 6.90 (SD) versus 14.57 ± 6.07 (SD), two-tailed Mann-Whitney U-value 708.5, P = 0.028], as well as a higher mean CMTESv2-R indicating a higher burden of accrued disability over the same time-frame. Both groups had a moderate mean CMTPedS score [AD-CMT2A mean 26.45 ± 10.26 (SD) and AR-CMT2A mean 27.00 ± 11.31 (SD)] but with no significant difference between them. There were no statistically significant differences between the two groups in the use of walking aids (29% versus 47%) or wheelchair (26% versus 20%), dexterity difficulties (64% versus 79%), optic nerve atrophy (7% versus 20%), hearing loss (both 7%) or scoliosis (12% versus 29%).

---

### Charcot-Marie-Tooth disease type 4C: novel mutations, clinical presentations, and diagnostic challenges [^113kAiG2]. Muscle & Nerve (2018). Low credibility.

Introduction

This study analyzes and describes atypical presentations of Charcot-Marie-Tooth disease type 4C (CMT4C).

Methods

We present clinical and physiologic features of 5 patients with CMT4C caused by biallelic private mutations of SH3TC2.

Results

All patients manifested scoliosis, and nerve conduction study indicated results in the demyelinating range. All patients exhibited signs of motor impairment within the first years of life. We describe 2 or more different genetic diseases in the same patient, atypical presentations of CMT, and 3 new mutations in CMT4C patients.

Discussion

A new era of unbiased genetic testing has led to this small case series of individuals with CMT4C and highlights the recognition of different genetic diseases in CMT4C patients for accurate diagnosis, genetic risk identification, and therapeutic intervention. The phenotype of CMT4C, in addition, appears to be enriched by a number of features unusual for the broad CMT category. Muscle Nerve 57: 749–755, 2018.

---

### Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: a French cohort study [^116BqDrM]. European Journal of Neurology (2025). Medium credibility.

Abstract

Background and purpose

X‐linked Charcot‐Marie‐Tooth disease type 1 (CMTX1) ranks as the second most prevalent hereditary neuropathy and, currently, has no definitive cure. Emerging preclinical trials offer hope for potential clinical studies in the near future. While it is widely accepted that experimental groups in these trials should be balanced for age and gender, there is a current shortfall in data regarding phenotype–genotype correlations. Our aim was to provide a more detailed understanding of these correlations to facilitate the formation of well‐matched patient groups in upcoming clinical trials.

Methods

We conducted a retrospective evaluation of CMTX1 patients from 13 designated reference centers in France. Data on genetics, clinical features, and nerve conduction were systematically gathered.

Results

We analyzed the genotype–phenotype correlations in 275 CMTX1 patients belonging to 162 families and carrying 87 distinct variants. Patients with variants affecting the transmembrane domains demonstrated significantly greater severity, as evidenced by a Charcot‐Marie‐Tooth Examination Score of 10.5, compared to 7.1 for those with intracellular domain variants and 8.7 for extracellular domain variants (p < 0.000). These patients also experienced an earlier age of onset, showed slower ulnar nerve conduction velocities and had more substantial loss of motor amplitude.

Conclusions

This study confirms the presence of a correlation between the mutated protein domain and the clinical phenotype. Patients with a variant in the transmembrane domains demonstrated a more severe clinical and electrophysiological profile. Consequently, the genotype could play a prognostic role in addition to its diagnostic role, and it will be essential to consider this in future clinical trials.

---

### Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: a French cohort study [^115axzm4]. European Journal of Neurology (2025). Medium credibility.

INTRODUCTION

X‐linked Charcot‐Marie‐Tooth disease (CMTX1) is caused by mutations in the GJB1 gene, which encodes the connexin 32 protein. It is the second most prevalent form of Charcot‐Marie‐Tooth disease (CMT), accounting for approximately 10% of all CMT cases. This is preceded only by CMT1A, which makes up 62% of cases, and followed by CMT2A at 7%. Like other forms of CMT, CMTX1 results in length‐dependent sensory and motor neuropathy. However, due to its X‐linked inheritance pattern, males are generally more severely affected than females. Unique features of CMTX1 include central nervous system manifestations such as stroke‐like symptoms, varied motor conduction velocities, and possible motor conduction blocks.

Connexin 32 is expressed both in the peripheral and central nervous systems. Like other connexins, it is a membrane protein situated in gap junction channels. This protein serves as a subunit that assembles in groups of six to form a hemichannel, also known as a connexon. These connexons are subsequently transported to the plasma membrane, where they pair with connexons from adjacent cells to create a gap junction channel. This channel structure facilitates direct cellular communication through layers of myelin, enabling the transit of small molecules, such as ions, while preventing the passage of larger proteins.

Over 400 variants of the GJB1 gene have been documented. The majority of these are missense variants, but nonsense and frameshift variants have also been identified. Cases of complete deletion and variations in the non‐coding regions of the gene have also been reported but are rarer.

Current data on genotype–phenotype correlations in CMTX1 are limited. Although initial studies hinted at such a correlation, subsequent research across multiple cohorts has failed to consistently validate this relationship. A recent large multicenter cohort study by Record et al. found that patients with missense variants in the intracellular domain generally exhibited a milder phenotype compared to those with variants in the various transmembrane domains (TM 1, 2 and 3) and the second extracellular domain (EC 2).

Furthermore, no significant initial clinical or neurophysiological differences were observed between patients categorized as having variants of uncertain significance (VUS) and those deemed to have pathogenic or likely pathogenic variants. However, disease progression did vary significantly over 1 and 2 years of follow‐up, although these differences were no longer evident after 2 years. That suggests that patients with a VUS could potentially be reclassified as patients with likely pathogenic variants.

---

### Charcot-Marie-Tooth disease subtypes and genetic testing strategies [^115oPT56]. Annals of Neurology (2011). Low credibility.

Objective

Charcot-Marie-Tooth disease (CMT) affects 1 in 2,500 people and is caused by mutations in more than 30 genes. Identifying the genetic cause of CMT is often necessary for family planning, natural history studies, and for entry into clinical trials. However genetic testing can be both expensive and confusing to patients and physicians.

Methods

We analyzed data from 1,024 of our patients to determine the percentage and features of each CMT subtype within this clinic population. We identified distinguishing clinical and physiological features of the subtypes that could be used to direct genetic testing for patients with CMT.

Results

Of 1,024 patients evaluated, 787 received CMT diagnoses. A total of 527 patients with CMT (67%) received a genetic subtype, while 260 did not have a mutation identified. The most common CMT subtypes were CMT1A, CMT1X, hereditary neuropathy with liability to pressure palsies (HNPP), CMT1B, and CMT2A. All other subtypes accounted for less than 1% each. Eleven patients had > 1 genetically identified subtype of CMT. Patients with genetically identified CMT were separable into specific groups based on age of onset and the degree of slowing of motor nerve conduction velocities.

Interpretation

Combining features of the phenotypic and physiology groups allowed us to identify patients who were highly likely to have specific subtypes of CMT. Based on these results, we propose a strategy of focused genetic testing for CMT, illustrated in a series of flow diagrams created as testing guides.

---

### Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development [^114vWxAK]. Journal of Neurology, Neurosurgery, and Psychiatry (2019). Medium credibility.

Charcot-Marie-Tooth disease, a heterogeneous hereditary motor and sensory neuropathy

Charcot-Marie-Tooth neuropathy (CMT) is the most common hereditary motor and sensory neuropathy with an estimated worldwide prevalence of 1 in 2500. The disease was named after the three neurologists, Jean-Martin Charcot, Pierre Marie and Howard Henry Tooth, who first described the disease in 1886.CMT is a clinically and genetically heterogeneous disease, affecting both children and adults. Patients typically exhibit a slowly progressive and length-dependent degeneration of their peripheral nerves resulting in muscle weakness, atrophy in the feet and legs which extend later to the hands, causing reduced tendon reflexes and slight to moderate distal sensory impairment. Foot deformities like pes cavus (high-arched foot deformity) is among the frequently reported manifestations of CMT, with patients sometimes also exhibiting hearing loss and hip dysplasia. These and other additional symptoms that mark the different CMT subtypes may cause a significant decrease in the quality of life of affected individuals.

---

### Risk of fracture in patients with Charcot-Marie-Tooth disease [^114L2Yf4]. Muscle & Nerve (2014). Low credibility.

Introduction

In this study we evaluated fracture risk in patients with Charcot-Marie-Tooth (CMT) disease.

Methods

We conducted a retrospective cohort study using the UK Clinical Practice Research Datalink (1987–2012). Each patient with CMT disease was matched with up to 6 patients without a history of CMT disease. The outcome measure was fractures.

Results

The risk of non-osteoporotic fracture was statistically significantly increased [adjusted hazard ratio (AHR) 1.47, 95% confidence interval (CI) 1.01–2.14], whereas risk of any and osteoporotic fracture did not reach statistical significance compared with control patients [AHR 1.31 (95% CI 0.98–1.74) and AHR 1.10 (95% CI 0.69–1.74), respectively].

Conclusions

CMT patients have a 1.5-fold increased risk for non-osteoporotic fracture. Studies with larger numbers of CMT patients and with additional data on CMT subtype, bone mineral density, and functional status should be performed to confirm a true association between CMT and an increased risk of fracture.

---

### Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: a French cohort study [^111jaGT3]. European Journal of Neurology (2025). Medium credibility.

Variants of uncertain significance

In our patient cohort, relying solely on ClinVar classifications for "pathogenic" or "likely pathogenic" would severely limit eligibility for clinical trials: only 156 of 275 patients carrying 31 out of 87 identified variants would qualify. This is particularly problematic considering that 25% of the variants in our cohort are classified as VUS on ClinVar. Such a high proportion of VUS poses significant logistical challenges for clinical trials, especially given the slow progression of the disease, which necessitates larger sample sizes to discern meaningful differences between treatment and control groups.

Most of these variants remain in the VUS category mainly because they are unique to single families and lack sufficient functional evidence to support their pathogenicity.

On a positive note, the application of computational classification tools, such as Franklin Genoox, has the potential to ameliorate this issue. In our cohort, such tools increased the number of variants classified as pathogenic from 31 to 74 out of 87, thereby expanding the pool of eligible patients for clinical trials. Moreover, our data show that patients with variants classified as VUS have clinical profiles similar to those with pathogenic variants. This finding aligns well with previous work, notably the study conducted by Record et al. We can suggest that patients carrying VUS, if the variant segregates in the family and if the clinical presentation is compatible, could be reasonably included in clinical trials without introducing significant bias. While VUS classifications can represent a barrier to research, strategies such as computational reclassification and broader clinical inclusion criteria could mitigate this issue and facilitate the conduct of meaningful clinical trials.

Variants classified as benign or likely benign

Our patients with variants classified as benign or likely benign did exhibit a clinical phenotype and a conduction study consistent with CMTX1. These variants may have been misclassified due to their location: either in the non‐coding 5'UTR domain or in the C‐terminal domain. Variants in the C‐terminal domain, especially beyond amino acid 215, may be located in regions less critical for the protein's essential functions, which could explain why these variants are classified as benign. However, we did not find a significant difference in our cohort between the 12 patients carrying a variant beyond amino acid 215 and others. As for variants in non‐coding domains, the significant lack of data could explain why these variants are classified as benign.

---

### Frequency, entity and determinants of fatigue in Charcot-Marie-Tooth disease [^115PzCzd]. European Journal of Neurology (2023). Medium credibility.

FUNDING INFORMATION

This work was funded by Telethon‐Italy Foundation grant GUP13006 and partially supported by the Italian Ministry of Health (RRC).

---

### X-linked Charcot-Marie-Tooth disease predominates in a cohort of multiethnic Malaysian patients [^111bcCSv]. Muscle & Nerve (2014). Low credibility.

Introduction

Data regarding Charcot-Marie-Tooth disease is lacking in Southeast Asian populations. We investigated the frequency of the common genetic mutations in a multiethnic Malaysian cohort.

Methods

Patients with features of Charcot-Marie-Tooth disease or hereditary liability to pressure palsies were investigated for PMP22 duplication, deletion, and point mutations and GJB1, MPZ, and MFN2 point mutations.

Results

Over a period of 3 years, we identified 25 index patients. A genetic diagnosis was reached in 60%. The most common were point mutations in GJB1, accounting for X-linked Charcot-Marie-Tooth disease (24% of the total patient population), followed by PMP22 duplication causing Charcot-Marie-Tooth disease type 1A (20%). We also discovered 2 novel GJB1 mutations, c.521C > T (Proline174Leucine) and c.220G > A (Valine74Methionine).

Conclusions

X-linked Charcot-Marie-Tooth disease was found to predominate in our patient cohort. We also found a better phenotype/genotype correlation when applying a more recently recommended genetic approach to Charcot-Marie-Tooth disease.

---

### Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study [^1167CZMi]. Brain (2020). Medium credibility.

MFN2 variant curation and classification

For conciseness, we hereafter use the term autosomal dominant (AD) CMT2A (AD-CMT2A) to refer to all the cases that carry a heterozygous variant in MFN2, irrespective of whether the variant was parentally inherited or occurred de novo. In our study, we used pathogenicity criteria from both pathogenic and benign categories (Supplementary Table 2) as published in the American College of Medical Genetics and Genomics and Association for Molecular Pathology (ACMG/AMP) guidelines, and classified all MFN2 variants into pathogenic, likely pathogenic and variants of uncertain significance (Supplementary Tables 3 and 4). The most recent Association for Clinical Genomic Science (ACGS) recommendations on variant classification were also taken into consideration to appropriately use downgraded or upgraded pathogenicity criteria in cases/pedigrees that could not be fully classified on the ACMG/AMP guidance alone. The ACMG/AMP guidelines suggest using the PP1 criterion (segregation data) as a stronger evidence with increasing segregation data; however, they do not provide a quantification for this. Therefore, we used the Jarvik and Browning guidance on how to quantify segregation data from multiple affected family members and appropriately assign pathogenicity criteria to that variant. Briefly, the product of all informative meioses across all affected members from all unrelated families was used to determine if the segregation criterion can be used as a supporting (PP1), moderate (PP1_moderate) or strong (PP1_strong) level of evidence based on probabilistic preset cut-offs between the three categories. We also used the REVEL meta-predictor tool, which combines pathogenicity and conservation scores from individual in silico prediction tools. The REVEL-derived aggregate score is more accurate compared to the combination of individual tools, which often assess overlapping subsets of evidence, thus inadvertently leading to 'double-counting' of evidence.

---

### Charcot-Marie-Tooth disease (CMT): distinctive phenotypic and genotypic features in CMT type 2 [^1146DbZY]. Journal of the Neurological Sciences (2001). Low credibility.

Charcot-Marie-Tooth disease (CMT), or hereditary motor and sensory neuropathy (HMSN), includes two main subtypes of CMT1/HMSN I (demyelinating), and CMT2/HMSN II (axonal). Further heterogeneity has been demonstrated by genetic molecular studies, with at least four responsible genes for CMT1. As for CMT2, a mutation in the neurofilament-light (NF-L) gene has been identified in a single family, and other CMT2 loci have been mapped. We propose a clinical classification of the CMT2 phenotypes, and review the features of the identified CMT2 genotypes. The following main subtypes of CMT2 are considered in the phenotype classification: classical CMT2, the variants of CMT2 showing atypical features that may represent either variance in the classical CMT2 phenotype or separate entities; CMT2 plus, i.e. complex forms with involvement of additional neural structures. The recognized CMT2 genotypes include: CMT2A (mapped to chromosome 1p35-36); CMT2B (3q13-22); CMT2C (with vocal cord paresis); CMT2D (7p14); CMT2E, related to a mutation in the NF-L gene on chromosome 8p21; proximal CMT2, or HMSN P (3q13.1); CMT2 with MPZ mutations; autosomal recessive CMT2 (1q21.2-q21.3); agenesis of the corpus callosum with sensorimotor neuronopathy (15q13-q15); CMT2 X-linked with deafness and mental retardation (Xq24-q26). The identified genotypes may correspond to previously described clinical subtypes of CMT2. In particular, classical CMT2 presents in association with NF-L gene mutation, in the only CMT2 family with known gene mutation, and in CMT2A patients. However, the features of classical CMT2 have been paradoxically reported also in families with MPZ mutation, and conversely several CMT2 families are not linked to the known CMT2 loci. Further cloning of the CMT2 genes will ultimately shed light on the pathogenic mechanism(s) implicated in the process of axonal degeneration, shared by the different CMT2 genotypes.

---

### Molecular pathogenesis of hereditary motor, sensory and autonomic neuropathies [^114WQRcb]. Current Opinion in Neurology (2001). Low credibility.

The hereditary motor, sensory and autonomic neuropathies are a heterogeneous group of neurological diseases. The classification of such is presently in a state of change. The original classification system was based on clinical findings whose limitations are being unfurled with increasing insights into the molecular basis of these disorders. In particular, much progress has been achieved in understanding the demyelinating forms of Charcot-Marie-Tooth (type 1), for which at least a dozen loci have been delineated and six genes identified. As anticipated, these genes play predominant roles in myelin biology. Four separate loci for the axonal Charcot-Marie-Tooth neuropathies (type 2) have been identified and only now are researchers beginning to tease out the responsible genes and the underlying molecular mechanisms. Similarly, progress is being made with the pure hereditary motor neuropathies. This review presents an updated list of genes responsible for inherited peripheral neuropathies and explores the underlying molecular mechanisms actively being investigated.

---

### Hereditary neuropathies [^1129ukym]. Current Opinion in Neurology (2003). Low credibility.

Purpose Of Review

This review will update recent advances in the genetics, clinico-electrophysiological, pathological data and pathophysiology of Charcot-Marie-Tooth disease and related disorders.

Recent Findings

Hereditary neuropathies continue to be in a state of constant flux, reflecting the rapid advances in the description of causative genes, three additional Charcot-Marie-Tooth genes having been identified in recent months. Such an ever-increasing body of genetic data provides valuable clues to the pathogenetic mechanisms of both nerve demyelination and nerve axonal degeneration. The classification of Charcot-Marie-Tooth disease is increasingly more complex as there are approximately 26 loci; for clinicians to reach a simplified classification is a pressing need. Genotypic-phenotypic correlations are still incomplete and will require further research, starting from both refined molecular investigations and detailed clinical, electrophysiological, and pathological studies. Recent epidemiological surveys have corroborated the fact that Charcot-Marie-Tooth disease is the most common type of hereditary neuropathy.

Summary

Advances in molecular genetics in hereditary neuropathies, and mainly in Charcot-Marie-Tooth disease, have enriched our knowledge of this heterogeneous group of disorders. In spite of this there remain important and basic issues, such as an updated and revised classification of Charcot-Marie-Tooth disorders, the better delineation of phenotypic-genotypic correlations, and further research to map as yet non-localized loci or to identify unknown gene mutations.

---

### Mild early onset axonal Charcot-Marie-Tooth disease not linked to other axonal Charcot-Marie-Tooth loci [^115XYVMh]. Neurology (2005). Low credibility.

Autosomal dominant axonal Charcot-Marie-Tooth disease type 2 (CMT2) is a heterogeneous group of disorders with seven chromosomal loci mapped in the uncomplicated forms of CMT2. The authors report clinical, electrophysiologic, and genetic analysis of a Polish CMT2 family. Nine known CMT2 gene loci and one MPZ gene locus have been excluded. The authors' findings suggest that this family represents a novel form of CMT2 disease.

---

### Updating the classification of inherited neuropathies: results of an international survey [^113iW4Nu]. Neurology (2018). Low credibility.

Objective

The continual discovery of disease-causing gene mutations has led to difficulties in the complex classification of Charcot-Marie-Tooth diseases (CMT) that needs to be revised.

Methods

We recently published a proposal to update the classification of inherited neuropathies. The reactions from colleagues prompted us to diffuse the proposal and ask people if they would be ready for such a change. We therefore performed an internet survey (from October 1, 2016, to December 1, 2016) that included more than 300 CMT worldwide specialists (practitioners and scientists) from various countries. A questionnaire (with proposals to update and simplify the way in which CMT is classified) was sent by e-mail to all participants in the last International Charcot-Marie-Tooth and Related Neuropathy Consortium meeting held in Venice, September 8–10, 2016 (as identified through an e-mail list).

Results

Of the 107 CMT specialists who answered the survey, 65% considered that changes are needed and that our proposals constituted an improvement over the historical classification of CMT.

Conclusions

Based on recent proposals in the medical literature, these results highlight that most specialists think that changes are needed to the classification of CMT.

---

### Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study [^115m9gSw]. Brain (2020). Medium credibility.

Results

A total of 225 patients with MFN2 variants were recruited in 19 INC centres in the US, UK, Italy and Australia (100 males: 125 females). Eighty-seven of these were children under the age of 20 years (43 males: 44 females) and the average age ± SD at enrolment for the entire cohort was 31.30 ± 19.88 years. The age distribution was considered as a single mode with an arbitrary cut-off at the age of 20 years, rather than bimodal, as there are no distinct paediatric and adult presentations in CMT2A.

We identified 179 patients from 133 families with dominant pathogenic (ACMG class 5) or likely pathogenic (class 4) MFN2 variants (AD-CMT2A; Supplementary Table 3), and 17 patients from 13 families with AR-CMT2A (Supplementary Table 5); 13 of 17 patients with AR-CMT2A harboured homozygous variants or compound heterozygous variants proven to be in trans phase. Twenty-nine patients from 23 families with variants of uncertain significance are also reported (Supplementary Table 4). For both the cross-sectional genotype-phenotype and longitudinal studies, only cases with pathogenic or likely pathogenic variants were considered.

---

### Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study [^114gmB8Y]. Brain (2020). Medium credibility.

Statistical analysis

Data were analysed mostly on an available basis. The chi-squared goodness-of-fit test (skewness, kurtosis, median, mean) was used to ascertain the distribution of data. The baseline demographics and characteristics, clinical data from the history and examination and the physical disability were analysed using descriptive statistics. Throughout the manuscript values describing continuous data represent the mean ± standard deviation (SD). Correlations between categorical data at baseline were assessed with chi-squared (χ²) or Fisher's exact test as appropriate. Correlations between the CMTESv2 and the disease duration as calculated at the baseline visit were assessed with two-tailed, Spearman's rank correlation coefficient. The longitudinal responsiveness of the CMTESv2, CMTESv2-R and CMTPedS was quantified as the standardized response mean [SRM = mean change/standard deviation (SD) change]. SRM-values of 0.20–0.49, 0.50–0.79, and ≥ 0.80 correspond to small, moderate, and large responsiveness, respectively as suggested originally. A two-tailed, paired Student's t -test was used to compare longitudinal changes in the CMTESv2, CMTESv2-R and CMTPedS. P ≤ 0.05 was considered statistically significant.

Data availability

The data that support the findings of this study are available from the corresponding author, upon reasonable request. The data are not publicly available since they contain information that could compromise the privacy of research participants.

---

### Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: a French cohort study [^116EhUoA]. European Journal of Neurology (2025). Medium credibility.

Variantclass

According to ClinVar, 31 variants (representing 36% of the total) were found in 156 patients from 95 families (58.6%) and were classified as either pathogenic or likely pathogenic. Another 25 variants, representing 29% of the dataset and identified in 70 patients from 35 families (21.6%), were categorized as VUS. Additionally, two variants (or 2% of the dataset) from two patients (two families) were deemed to be benign or likely benign. A total of 29 variants (33%) from 30 families (18.5%) were not listed (Figure 4a) in ClinVar.

FIGURE 4
American College of Medical Genetics classification of variants reported on (a) ClinVar or (b) based on their interpretation on Franklin Genoox. VUS, variants of uncertain significance.

Using the Franklin Genoox classification, 74 variants (or 85% of the total), found in 250 patients from 150 families, were classified as either pathogenic or likely pathogenic. Meanwhile, nine variants (or 10% of the dataset), observed in 20 patients from seven families, were classified as VUS. Furthermore, four variants (or 5% of the dataset), found in five patients from five families, were considered benign or likely benign (Figure 4b). Among the 29 variants not listed in ClinVar, Franklin Genoox interpreted 23 variants as pathogenic and six variants as VUS. Additionally, 20 variants classified as VUS in ClinVar were deemed pathogenic by Franklin Genoox. Detailed information on each variant, along with its ACMG classification according to both ClinVar and Franklin Genoox, can be found in Table S2. Interestingly, there were no discernible differences in the physiological and neurophysiological data among the patient groups classified as either pathogenic, VUS, benign, or those not reported in ClinVar. Similarly, no differences were observed among the patient groups classified as pathogenic, VUS, or benign based on the Franklin Genoox classification. The primary data for these groups are presented in Table 3.

TABLE 3
Phenotype of patients with X‐linked Charcot‐Marie‐Tooth disease, stratified by their American College of Medical Genetics classification based on interpretation on ClinVar or Franklin Genoox.

---

### Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study [^114uULX5]. Brain (2020). Medium credibility.

Of the 179 patients with AD-CMT2A, 92 patients had longitudinal data, of whom 38 had 1-year follow-up data and 34 had 2-year follow-up data. Eight patients with AR-CMT2A had longitudinal data, of whom six had 1-year follow-up data, four had 2-year follow-up data and five had 4-year follow-up data. The longitudinal data from the CMTESv2, the weighted CMTESv2-R and the CMTPedS of all AD-CMT2A and AR-CMT2A patients was used to calculate the mean change over 1 and 2 years for each group respectively. Subsequently the aggregated data were used to calculate the SRM of the CMTESv2, CMTESv2-R and CMTPedS over 1 and 2 years (Table 3). The SRM is a metric that describes how sensitive a particular outcome is to change. In patients with AD-CMT2A, the CMTESv2 increased significantly over 1 year [mean change 0.84 ± 2.42 (SD), two-tailed paired t -test P = 0.039]; the equivalent 1-year SRM at 0.35 showed small responsiveness. Surprisingly, the CMTESv2-R did not show a significant change over 1 year [mean change 0.63 ± 3.19 (SD), two-tailed paired t -test P = 0.230]. Over 2 years, the CMTESv2 increased significantly [mean change 0.97 ± 1.77 (SD), two-tailed paired t -test P = 0.003], as did the CMTESv2-R [mean change 1.21 ± 2.52 (SD), two-tailed paired t -test P = 0.009], and their 2-year SRM values of 0.55 and 0.48 reflect moderate and small responsiveness, respectively. Analysis of the CMTPedS in all the paediatric AD-CMT2A and AR-CMT2A cases grouped together, showed that it increased significantly over 1 year (mean change 2.24 ± 3.09; two-tailed paired t -test P = 0.009) and over 2 years (mean change 4.00 ± 3.79; two-tailed paired t -test P = 0.031) with respective SRMs of 0.72 and 1.06. There was no significant change in the CMTESv2 or CMTESv2-R in the AR-CMT2A group and this is likely to be due to the small sample size of patients with available follow-up data from baseline.

---

### Next-generation sequencing in Charcot-Marie-Tooth: a proposal for improvement of ACMG guidelines for variant evaluation [^111sm8uY]. Journal of Medical Genetics (2024). Medium credibility.

Background

The application of massive parallel sequencing technologies in the molecular analysis of Charcot-Marie-Tooth (CMT) has enabled the rapid and cost-effective identification of numerous potentially significant variants for diagnostic purposes. The objective is to reduce the number of variants, focusing only on those with pathogenic significance. The 2015 American College of Medical Genetics and Genomics (ACMG) guidelines aid in achieving this goal, but it is now evident that a pathology or gene-specific review of these rules is essential to avoid misinterpretations that may result from blindly applying the criteria. This study demonstrates how revised ACMG criteria, combined with CMT-specific literature data and expertise, can alter the final classification of a variant.

Methods

We reviewed ACMG criteria based on current knowledge of CMT and provided suggestions for adapting them to the specificities of CMT.

Results

Of the 226 index patients analysed, a diagnostic yield of 20% was obtained. It is worth noting that the 9% of cases had their final diagnosis changed with the application of the revised criteria, often resulting in the loss of the pathogenic classification of a variant.

Conclusions

The widespread availability of high-throughput sequencing technologies has enabled genetic testing even for laboratories without specific disease expertise. Disease-specific ACMG criteria can be a valuable tool to prevent the proliferation of variants of uncertain significance and the misinterpretation of variants.

---

### Charcot-Marie-Tooth disease and related hereditary polyneuropathies: molecular diagnostics determine aspects of medical management [^111GTmk3]. Genetics in Medicine (2006). Low credibility.

Purpose

An evidence-based approach was used to determine the frequency distribution of genes contributing to the Charcot-Marie-Tooth (CMT) disease phenotype.

Methods

We performed a combined analysis of 11 population-based studies from various ethnic backgrounds to generate an evidence-based testing scheme. To estimate the relative frequencies of the responsible genes for which population-based studies are not available, we used our cohort of clinically classified patients with CMT and related neuropathies collected before the availability of genetic testing.

Results

Similar mutation frequencies were detected in the various studies, revealing a uniform distribution of pathogenic mutations. In CMT1 70% of patients harbor the CMT1A duplication, followed by GJB1 mutations at 8.8%. MPZ and PMP22 mutations are less common, identified on average in 2.9% and 1.5% of patients, respectively. Other genes not tested in population-based studies contribute to less than 1% of disease individually. In CMT2 MFN2 mutations are the most common, although population-based studies are not yet available.

Conclusion

CMT represents a heterogeneous group of disorders at the molecular level. Nevertheless, testing for the CMT1A duplication (i.e., duplication of PMP22) alone yields an accurate molecular diagnosis in approximately half of all patients. If one further specifies the clinical type (demyelinating vs. axonal), the yield of detecting a molecular defect increases to 75% to 80% in the demyelinating or CMT1 group with a screening test that evaluates for CMT1A duplication/hereditary neuropathy with liability to pressure palsies deletion and GJB1 point mutations.

---

### A retrospective review of X-linked Charcot-Marie-Tooth disease in childhood [^116PUBjt]. Neurology (2011). Low credibility.

Objective

X-linked Charcot-Marie-Tooth disease (CMTX) is infrequently diagnosed in childhood, and its clinical and neurophysiologic features are not well-described. We reviewed clinical, neurophysiologic, and pathologic findings in 17 children with CMTX.

Methods

This was a retrospective review of children with CMTX from 2 tertiary pediatric hospitals. The diagnosis of CMTX was based on an identifiable connexin 32 mutation (CMTX1) or a consistent pedigree and neurophysiologic features in children without a connexin 32 mutation (CMTX-other).

Results

Six boys and 2 girls from 8 kindreds had CMTX1, and 8 boys and 1 girl from 5 kindreds had other forms of CMTX (CMTX-other). Fifteen children, including males and carrier females, were symptomatic from infancy or early childhood (younger than 5 years). In addition to the typical Charcot-Marie-Tooth disease clinical phenotype, some patients had delayed motor development, sensorineural hearing loss, tremor, pathologic fractures, or transient CNS disturbances. Eleven children underwent nerve conduction studies. Median nerve motor nerve conduction velocities were in the intermediate to normal range (30–54 m/s) in all children older than 2 years. Axon loss, reflected by low-amplitude compound muscle action potentials, was present in all patients. A pattern of X-linked dominant inheritance, with carrier females showing an abnormal neurologic or neurophysiologic examination, correlated with the presence of a connexin 32 mutation in all but 2 pedigrees.

Conclusions

The clinical phenotype of CMTX is broader than previously reported. Onset in males and carrier females is most often in early childhood. Families with an X-linked dominant inheritance pattern are likely to have CMTX1.

---

### Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing [^115LFMLs]. Journal of Neurology, Neurosurgery, and Psychiatry (2012). Low credibility.

Background

Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous group of diseases with approximately 45 different causative genes described. The aims of this study were to determine the frequency of different genes in a large cohort of patients with CMT and devise guidelines for genetic testing in practice.

Methods

The genes known to cause CMT were sequenced in 1607 patients with CMT (425 patients attending an inherited neuropathy clinic and 1182 patients whose DNA was sent to the authors for genetic testing) to determine the proportion of different subtypes in a UK population.

Results

A molecular diagnosis was achieved in 62.6% of patients with CMT attending the inherited neuropathy clinic; in 80.4% of patients with CMT1 (demyelinating CMT) and in 25.2% of those with CMT2 (axonal CMT). Mutations or rearrangements in PMP22, GJB1, MPZ and MFN2 accounted for over 90% of the molecular diagnoses while mutations in all other genes tested were rare.

Conclusion

Four commonly available genes account for over 90% of all CMT molecular diagnoses; a diagnostic algorithm is proposed based on these results for use in clinical practice. Any patient with CMT without a mutation in these four genes or with an unusual phenotype should be considered for referral for an expert opinion to maximise the chance of reaching a molecular diagnosis.

---

### Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: a French cohort study [^116VVZKn]. European Journal of Neurology (2025). Medium credibility.

FIGURE 2
(a) Charcot‐Marie‐Tooth Examination Score (CMTES) and (b) Overall Neuropathy Limitation Score (ONLS) of patients carrying a missense variant, by their mutated protein domain. Transmembrane domains (TM) are depicted with stripes. * Significance at < 0.05, < 0.01. C term, C‐terminal domain; EC, extracellular domain; IC, intracellular domain; N term, N‐terminal domain.

When categorizing the domains into three groups, we identified 22 variants in 64 patients from 42/134 families (31%) in the intracellular domains, 25 variants in 72 patients from 47/134 families (35%) in the transmembrane domains, and 26 variants in 94 patients from 45/134 families (34%) in the extracellular domains (Table 1). Gender distribution and age at evaluation were comparable among these groups. Patients with a missense variant in the transmembrane domains exhibited significantly more severe symptoms than those with variants in either the intracellular or extracellular domains. This was evident in terms of CMTES (10.5 vs. 7.1 and 8.7; p < 0.000), ONLS (3.6 vs. 2.3 and 2.4, p < 0.000), age of disease onset (13 years vs. 22 and 20 years; p < 0.000), and utilization of orthoses (60% vs. 47% and 41%; p = 0.045). There was also a difference among the three groups concerning the conduction velocities of the ulnar (p = 0.025) and median nerves (p = 0.017), which were slower in patients with a missense variant in transmembrane domains, as well as the sum of CMAPs (p = 0.002), which were lower in patients with a missense variant in transmembrane domains. These results are graphically represented in Figure 3.

---

### A review of genetic counseling for Charcot Marie Tooth disease (CMT) [^113RGisL]. Journal of Genetic Counseling (2013). Low credibility.

Charcot Marie Tooth disease (CMT) encompasses the inherited peripheral neuropathies. While four genes have been found to cause over 90% of genetically identifiable causes of CMT (PMP22, GJB1, MPZ, MFN2), at least 51 genes and loci have been found to cause CMT when mutated, creating difficulties for clinicians to find a genetic subtype for families. Here, the classic features of CMT as well as characteristic features of the most common subtypes of CMT are described, as well as methods for narrowing down the possible subtypes. Psychosocial concerns particular to the CMT population are identified. This is the most inclusive publication for CMT-specific genetic counseling.

---

### Hereditary neuropathies [^117UsSfP]. Current Opinion in Neurology (2007). Low credibility.

Purpose Of Review

The purpose of this review is to help neurologists understand new concepts in hereditary neuropathies, from the clinician's point of view, in the molecular era after the burst of information regarding peripheral nerve biology.

Recent Findings

Recent studies have focused on understanding the pathomechanisms involved in hereditary neuropathies. In the past year identification of new genes has slowed down since scientists have concentrated more on the function of genes causing Charcot-Marie-Tooth disease and Schwann cell-axon interactions to reveal the molecular cell biology of the disease. Animal models for the most common subtypes of human Charcot-Marie-Tooth disease are now available.

Summary

Rapid advances in the molecular genetics and cell biology of hereditary neuropathies have highlighted the great genetic complexity of Charcot-Marie-Tooth disease. The evolution from a simple clinical classification to a complex molecular one has not facilitated our understanding of the disease. Moreover, the new molecular classification is not simple to use as different mutations of the same gene produce a range of phenotypes. The clinicians have to look for specific clinical and electrophysiological clues to direct the patient to appropriate genetic testing.

---

### Whole genome sequencing increases the diagnostic rate in Charcot-Marie-Tooth disease [^115sYBAo]. Brain (2024). Medium credibility.

Results

Overall diagnostics

One thousand six hundred and forty-seven patients were seen with inherited neuropathy, which included 132 with hereditary ATTR amyloidosis (not included for analysis in this study), leaving 1515 with CMT and related disorders. The cohort comprised the following individual case numbers: CMT1, 621 (41.0%); CMT2, 294 (19.4%); CMTi, 205 (13.5%); HMN, 139 (9.2%); HSN, 93 (6.1%); SAN, 38 (2.5%); HNPP, 72 (4.8%); and complex neuropathies, 53 (3.5%) (Fig. 2).

Figure 2
Diagnostic breakdown by phenotype. CMT1/2 = Charcot-Marie-Tooth disease type 1/2; CMT(i) = Charcot-Marie-Tooth disease (intermediate); HMN = hereditary motor neuropathy; HSN = hereditary sensory neuropathy; SAN = sensory ataxic neuropathy.

---

### Peripheral neuropathies: molecular diagnosis of Charcot-Marie-Tooth disease [^113FnTLh]. Nature Reviews: Neurology (2011). Medium credibility.

Charcot–Marie–Tooth disease (CMT) is a hereditary neuropathy attributed to mutations in more than 30 different genes. A recent study identified the causative mutation in 67% of 787 screened patients with CMT, and the findings raise important issues concerning genetic testing for CMT.

---

### Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: a French cohort study [^114MypgS]. European Journal of Neurology (2025). Medium credibility.

TABLE 1
Phenotype of missense variants causing X‐linked Charcot‐Marie‐Tooth disease, stratified by structural domain of connexin 32.

FIGURE 3
Phenotype of missense variants causing X‐linked Charcot‐Marie‐Tooth disease, by structural domain of the connexin 32. Intracellular domain (IC), including N‐terminal domain: AA 1‐19; IC: AA 93‐130 and C‐terminal domain: AA 208‐283; transmembrane domain (TM), including first TM (TM 1): AA 20‐38, second TM (TM 2): AA 74‐92, third TM (TM 3): AA 131‐148 and fourth TM (TM 4): AA 188‐207. Extracellular domain (EC), including first EC (EC 1): AA 39‐73 and second EC (EC 2): AA 149‐187. * Significance at < 0.05, **< 0.01, **< 0.001. CMAP, compound muscle action potential; CMTES, Charcot‐Marie‐Tooth Examination Score; MNCV, motor nerve conduction velocity; ONLS, Overall Neuropathy Limitation Score.

---

### Pitt-hopkins syndrome in a boy with Charcot Marie Tooth disease type 1A: a rare co-occurrence of 2 genetic disorders [^115nygbi]. Journal of Child Neurology (2012). Low credibility.

Pitt-Hopkins syndrome is characterized by marked intellectual impairment, hyperventilation episodes, and dysmorphic facial features. This article reports a boy who presented with developmental delay, facial dysmorphism, microcephaly, hypotonia, and areflexia. He was initially diagnosed with Charcot Marie Tooth disease type 1A based on family history and genetic testing. However, severe mental impairment was atypical of Charcot Marie Tooth disease type 1A. Over the next few years he developed characteristic breathing abnormality, hand stereotypies, seizures, and marked constipation. The evolution of these manifestations coupled with the characteristic facial appearance suggested the additional diagnosis of Pitt-Hopkins syndrome, which was confirmed by the genetic defect of the transcription factor 4 on chromosome 18. This case demonstrates the rare co-occurrence of 2 genetic disorders in the same individual.

---

### Phenotypic variability of childhood Charcot-Marie-Tooth disease [^111KNcpy]. JAMA Neurology (2016). Medium credibility.

Importance

Disease severity of childhood Charcot-Marie-Tooth disease (CMT) has not been extensively characterized, either within or between types of CMT to date.

Objective

To assess the variability of disease severity in a large cohort of children and adolescents with CMT.

Design, Setting, and Participants

A cross-sectional study was conducted among 520 children and adolescents aged 3 to 20 years at 8 universities and hospitals involved in the Inherited Neuropathies Consortium between August 6, 2009, and July 31, 2014, in Australia, Italy, the United Kingdom, and the United States. Data analysis was conducted from August 1, 2014, to December 1, 2015.

Main Outcomes and Measures

Scores on the Charcot-Marie-Tooth Disease Pediatric Scale (CMTPedS), a well-validated unidimensional clinical outcome measure to assess disease severity. This instrument includes 11 items assessing fine and gross motor function, sensation, and balance to produce a total score ranging from 0 (unaffected) to 44 (severely affected).

Results

Among the 520 participants (274 males) aged 3 to 20 years, CMT type 1A (CMT1A) was the most prevalent type (252 [48.5%]), followed by CMT2A (31 [6.0%]), CMT1B (15 [2.9%]), CMT4C (13 [2.5%]), and CMTX1 (10 [1.9%]). Disease severity ranged from 1 to 44 points on the CMTPedS (mean [SD], 21.5 [8.9]), with ankle dorsiflexion strength and functional hand dexterity test being most affected. Participants with CMT1B (mean [SD] CMTPedS score, 24.0 [7.4]), CMT2A (29.7 [7.1]), and CMT4C (29.8 [8.6]) were more severely affected than those with CMT1A (18.9 [7.7]) and CMTX1 (males: 15.3 [7.7]; females: 13.0 [3.6]) (P < .05). Scores on the CMTPedS tended to worsen principally during childhood (ages, 3–10 years) for participants with CMT4C and CMTX1 and predominantly during adolescence for those with CMT1B and CMT2A (ages, 11–20 years), while CMT1A worsened consistently throughout childhood and adolescence. For individual items, participants with CMT4C recorded more affected functional dexterity test scores than did those with all other types of CMT (P < .05). Participants with CMT1A and CMTX1 performed significantly better on the 9-hole peg test and balance test than did those with all other types of CMT (P < .05). Participants with CMT2A had the weakest grip strength (P < .05), while those with CMT2A and CMT4C exhibited the weakest ankle plantarflexion and dorsiflexion strength, as well as the lowest long jump and 6-minute walk test distances (P < .05). Multiple regression modeling identified increasing age (r = 0.356, β = 0.617, P < .001) height (r = 0.251, β = 0.309, P = 0.002), self-reported foot pain (r = 0.162, β = .114, P = 0.009), and self-reported hand weakness (r = 0.243, β = 0.203, P < .001) as independent predictors of disease severity.

Conclusions and Relevance

These results highlight the phenotypic variability within CMT genotypes and mutation-specific manifestations between types. This study has identified distinct functional limitations and self-reported impairments to target in future therapeutic trials.

---

### Controversies in the management of active Charcot neuroarthropathy [^111kVc93]. Therapeutic Advances in Endocrinology and Metabolism (2023). Medium credibility.

Despite these recommendations, a search of the four main clinical trial registries, only identified 17 trials on CN over the last 15 years, of which 10/17 (66.7%) were randomised controlled trials. Of these trials < 9/10 (90%) have investigated the use of pharmacological therapies to improve healing in CN. This review has shown that gaps remain in the evidence base for managing this condition.

The true prevalence of CN is still largely unknown. However, one study from Denmark estimated a 0–1 in every 2000 people will develop CN. In the USA figures state that approximately one in every 2500 Americans will experience CN. In the United Kingdom, a rare disease is defined as a condition which affects less than one, in 2000 people. This means that CN may not fit the definition of a 'rare disease'. However, there is definite overlap between the findings and recommendations of this review and the priorities of the UK Rare Disease Framework which are to:

Helping people get a final diagnosis faster.
Increasing awareness of rare diseases among healthcare professionals.
Better coordination of care.
Improving access to specialist care, treatments, and drugs.

This framework highlights the need for national and international collaboration to share knowledge and ideas, and complete high-quality research to ensure the best care and outcomes for people with rare diseases. For CN, this could mean developing a registry with internationally agreed definitions, of accurate up-to-date data on the incidence of CN, opportunities to examine and evaluate the effectiveness of current and new treatments for CN in larger populations, and to support researchers to identify people with CN likely to be willing to participate in research.

---

### Mortality of 196, 826 men and women working in U.S.-Based petrochemical and refinery operations: update 1979 to 2010 [^111CU97i]. Journal of Occupational and Environmental Medicine (2022). Medium credibility.

Motor Neuron Disease (MND) Including ALS and Other MNDs

We found the HWE to be less evident for the category of nervous system disease in the total cohort (SMR 0.91, 95% CI 0.85 to 0.96), primarily attributed to MND. MND mortality risks were significantly increased for both men and women in this study compared to the original study and SMRs remain significantly increased for the update period (2001 to 2010) for both genders (SDC Figure 11, SDC Figure 12).

However, for men working in upstream operations, a non-significantly increased mortality risk for MND-ALS was reported in the original study (SMR 1.47, 95% CI 0.78 to 2.51) based on 13 observed deaths. In this update, the SMR (1.28) for MND has decreased for this operating segment and continues to be non-statistically significant (95% CI 0.81 to 1.92).

In the absence of a unique ICD code for ALS, we used ICD-9 code 335.2 and ICD-10 code G12.2, which also include other MNDs. We found 82% (n = 125) of the death certificates (DCs) included the terms ALS or Lou Gehrig's disease, which we considered predictive of ALS, albeit not neurologically confirmed. This proportion in the MND class of diseases is consistent with the literature. About 2% (n = 3) of DCs indicated other MNDs such as bulbar palsy, primary lateral sclerosis and progressive muscular atrophy. For 11% (n = 17) of the DCs, progressive supranuclear palsy (n = 17), also known as Steele-Richardson Oslzewski syndromewas indicated. This is not a MND sub-type, and has a separate ICD-10 code of G23.1. The remaining 5% (n = 7) of certificates indicated the nonspecific term of motor neuron disease. While some physicians may use this term interchangeably with ALS, we found it may not always translate into ALS. For example, the MND term was next to "Kennedy's syndrome", which is a lower motor neuron, X-linked recessive disease, not ALS. Accuracy of ALS coding is expected to improve with the implementation of ICD-11 codes, which provide unique codes for ALS and each of the other MNDs.

---

### Mechanisms of disease: a molecular genetic update on hereditary axonal neuropathies [^111jpAP4]. Nature Clinical Practice: Neurology (2006). Medium credibility.

Hereditary axonal peripheral neuropathies comprise a genetically heterogeneous group of disorders that are clinically subsumed under the name of Charcot-Marie-Tooth (CMT) disease type 2 (CMT2). Historically, two classes of CMT have been differentiated: demyelinating forms of CMT (CMT1), in which nerve conduction velocities are decreased, and the axonal CMT2 forms, in which nerve conduction velocities are preserved. Recently, a number of genes that are defective in patients with the main forms of CMT2 have been identified. The molecular dissection of cellular functions of the related gene products has only just begun, and detailed pathophysiological models are still lacking. The known CMT2-related genes represent key players in these pathways, however, and are likely to provide powerful tools for identifying targets for future therapeutic intervention.

---

### ICD-10-CM | Classification of diseases, functioning, and… [^111qa2DR]. CDC (2024). Medium credibility.

What to know ICD-10-CM — the International Classification of Diseases, Tenth Revision, Clinical Modification — is used to code and classify medical diagnoses. ICD-10-CM is based on ICD-10, the system used to code and classify mortality data from death certificates. Use our free tool to search for ICD-10-CM codes. Introduction ICD-10-CM is a standardized system used to code diseases and medical conditions data. Healthcare providers use ICD-10-CM codes when diagnosing patients. ICD-10-CM builds on ICD-10 — the system used to code causes of death on death certificates. CDC's National Center for Health Statistics is responsible for the clinical modification of ICD-10 for use in the United States. The World Health Organization, which owns and publishes ICD-10, authorized NCHS to develop ICD-10-CM.

All modifications to ICD-10 must conform to WHO's established ICD structure and conventions. Special announcements Find ICD-10-CM codes NCHS provides a user-friendly, no-cost Browser Tool for the International Classification of Diseases, Tenth Revision, Clinical Modification. It includes updates from each year since the launch of ICD-10-CM. The browser tool allows users to:

- Search ICD-10-CM by code
- Search the ICD-10-CM Index by main term or sub-terms
- Search in a particular fiscal year update to find the right code for a specific date of service
- Toggle between Index and Tabular lists
- Find instructional information needed to understand ICD-10-CM codes NCHS adds all approved code set updates to the ICD-10-CM Browser Tool. Search ICD-10-CM Codes https: //icd10cmtool. cdc. gov/. Browsertoolfeatures-OfficialICD-10-CMCodingGuidelinesandPreface-ICD-10-CMBrowserToolUserGuide-ICD-10-CMTabularListofDiseasesandInjuries-ICD-10-CMIndextoDiseasesandInjuries-ICD-10-CMExternalCauseofInjuriesIndex-ICD-10-CMTableofNeoplasms-ICD-10-CMTableofDrugsandChemicals. Resources-ICD-10-PCS: ViewanddownloadtheprocedurecodingsystemdevelopedbytheCentersforMedicareandMedicaidServices-ICD-9-CM: FindinformationaboutthepreviousICDclinicalmodification-ICD-10-CMandICD-10-PCStransition: Getinformationandresourcesaboutthetransitiontothelatestrevisions-ClassificationofDeathandInjuryResultingfromTerrorism: VisittheCDCArchivetolearnhowICD-10andICD-10-CMcodeswereaddedaftertheterroristattacksofSeptember11, 2001.

---

### Clinical spectrum and frequency of Charcot-Marie-Tooth disease in Italy: data from the national CMT registry [^115EsiYZ]. European Journal of Neurology (2023). Medium credibility.

Background and Purpose

Data are reported from the Italian CMT Registry.

Methods

The Italian CMT Registry is a dual registry where the patient registers and chooses a reference center where the attending clinician collects a minimal dataset of information and administers the Charcot-Marie-Tooth (CMT) Examination/Neuropathy Score. Entered data are encrypted.

Results

Overall, 1012 patients had registered (535 females) and 711 had received a genetic diagnosis. Demyelinating CMT (65.3%) was more common than axonal CMT2 (24.6%) and intermediate CMT (9.0%). The PMP22 duplication was the most frequent mutation (45.2%), followed by variants in GJB1 and MPZ (both ~10%) and MFN2 (3.3%) genes. A relatively high mutation rate in some "rare" genes (HSPB1 1.6%, NEFL 1.5%, SH3TC2 1.5%) and the presence of multiple mutation clusters across Italy was observed. CMT4A was the most disabling type, followed by CMT4C and CMT1E. Disease progression rate differed depending on the CMT subtype. Foot deformities and walking difficulties were the main features. Shoe inserts and orthotic aids were used by almost one-half of all patients. Scoliosis was present in 20% of patients, especially in CMT4C. Recessive forms had more frequently walking delay, walking support need and wheelchair use. Hip dysplasia occurred in early-onset CMT.

Conclusions

The Italian CMT Registry has proven to be a powerful data source to collect information about epidemiology and genetic distribution, clinical features and disease progression of CMT in Italy and is a useful tool for recruiting patients in forthcoming clinical trials.

---

### Whole genome sequencing increases the diagnostic rate in Charcot-Marie-Tooth disease [^116jTh6f]. Brain (2024). Medium credibility.

We present for the first time, the diagnostic rate of a large, single, specialist inherited neuropathy centre after the introduction of WGS. Our overall diagnostic rate of 76.9% is the highest reported for a single CMT cohort. Although our officially reported diagnostic rate of WGS through the 100KGP is 31.8% (74/233), the true rate is 19.7% (46/233) as 28 of those recruited achieved their diagnosis through other testing methods prior to the release of 100KGP results. This value is nearly identical to the only other published WGS study in CMT, corroborating the current utility of the technology. Our diagnostic approach is primarily a phenotype-driven research analysis, combined with the specialist MDT. In the 'Results' section, we described different examples where WGS has led to a new diagnosis (e.g. SV analysis, non-coding variants and updating virtual panels) but these are underpinned for the most part by a detailed patient phenotype obtained after assessment in the specialist clinic. Groups, both in CMT and in other diseases, report this strategy amongst others, including a genotype-driven strategy with subsequent so-called 'reverse phenotyping', but this latter approach we feel is more appropriate for complex diseases where the pathology is often more widespread and there is better scope for phenotype expansion. The exception to this is for complex neuropathies where often systemic disorders are implicated and e.g. mitochondrial or metabolic variants may prompt reverse-phenotyping.

---

### Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study [^1146tY2b]. Brain (2020). Medium credibility.

The presence of a variant in the gnomAD population database was considered in the context of the disease prevalence, penetrance, genetic and allelic heterogeneity of CMT. A threshold of an allele count of 3 in gnomAD was used to distinguish between heterozygous variants that are plausible or not to be causal for CMT2A. Furthermore, all the variants described in autosomal recessive CMT2A cases (AR-CMT2A) in this study (Supplementary Table 5) had a gnomAD population allele frequency that would be compatible with the genetic architecture of autosomal recessive CMT as previously published. We have also detailed the benign (B) and likely benign (LB) variants we have encountered in our study and the reasons for their classifications (Supplementary Table 6).

Previously published case series and case reports of CMT2A were identified through an extensive PubMed literature review, the Inherited Neuropathy Variant Browser and ClinVar.

CMT clinical outcome measures

The clinical outcome measures used in this study included the CMT Neuropathy Score version 2 (CMTNSv2) and the Rasch modified CMTNSv2 (CMTNSv2-R), both composite scores based on patients' symptoms (three items), examination findings (four items), and electrophysiology (two items). The CMT Examination Score version 2 (CMTESv2) and Rasch modified version (CMTESv2-R) are subscores of the CMTNSv2 comprising seven items from the patients' symptoms and examination findings. The psychometrics of the Rasch weighting have only been performed in CMT1A patients and hence we used CMTESv2 as our primary clinical outcome measure for this study. Most assessment visits did not include neurophysiological studies and only the CMTESv2 and CMTESv2-R were obtained during these visits. Therefore, to maximize the sample size during the statistical analysis of the longitudinal data, the CMTESv2 and CMTESv2-R were primarily analysed; a similar analysis approach was also used in a CMT1A natural history study. We also analysed data obtained from the CMT Pediatric Scale (CMTPedS), a well-validated composite score that assesses strength, hand dexterity, sensation, gait, balance, power and endurance in children with CMT from the age of 3 years. For each of these scales a higher score indicates a higher level of impairment. Clinical investigators at each site received training in the administration of the clinical outcome measures and were certified clinical investigators prior to use.

---

### A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21 [^113EGwq2]. European Journal of Human Genetics (2001). Low credibility.

Charcot-Marie-Tooth disease (CMT) constitutes a genetically heterogeneous group of inherited motor and sensory peripheral neuropathies. The axonal type of CMT is designated CMT type 2 (CMT2). Four loci for autosomal dominant CMT2 have been reported so far. Only in CMT2E, linked to chromosome 8p21, disease-causing mutations in the gene for neurofilament light chain (NEFL) were identified. In this study we report a multigenerational Russian family with autosomal dominant CMT2 and assign the locus to chromosome 7q11-q21. The CMT2 neuropathy in this family represents a novel genetic entity designated CMT2F.

---

### Next-generation sequencing in Charcot-Marie-Tooth disease: opportunities and challenges [^112mM8kc]. Nature Reviews: Neurology (2019). High credibility.

Charcot-Marie-Tooth disease and the related disorders hereditary motor neuropathy and hereditary sensory neuropathy, collectively termed CMT, are the commonest group of inherited neuromuscular diseases, and they exhibit wide phenotypic and genetic heterogeneity. CMT is usually characterized by distal muscle atrophy, often with foot deformity, weakness and sensory loss. In the past decade, next-generation sequencing (NGS) technologies have revolutionized genomic medicine and, as these technologies are being applied to clinical practice, they are changing our diagnostic approach to CMT. In this Review, we discuss the application of NGS technologies, including disease-specific gene panels, whole-exome sequencing, whole-genome sequencing (WGS), mitochondrial sequencing and high-throughput transcriptome sequencing, to the diagnosis of CMT. We discuss the growing challenge of variant interpretation and consider how the clinical phenotype can be combined with genetic, bioinformatic and functional evidence to assess the pathogenicity of genetic variants in patients with CMT. WGS has several advantages over the other techniques that we discuss, which include unparalleled coverage of coding, non-coding and intergenic areas of both nuclear and mitochondrial genomes, the ability to identify structural variants and the opportunity to perform genome-wide dense homozygosity mapping. We propose an algorithm for incorporating WGS into the CMT diagnostic pathway.

---

### Diagnosis and new treatments in genetic neuropathies [^113Tc1S3]. Journal of Neurology, Neurosurgery, and Psychiatry (2009). Low credibility.

The genetic neuropathies are a clinically and genetically heterogeneous group of diseases of which the most common types are Charcot-Marie-Tooth disease (CMT), the hereditary sensory and autonomic neuropathies and the distal hereditary motor neuropathies. More than 30 causative genes have been described, making an accurate genetic diagnosis increasingly possible. Although no specific therapies are yet available, research into their pathogenesis has revolutionised our understanding of the peripheral nervous system and allowed the development of rational approaches to therapy. The first therapeutic trials in CMT are currently underway. This review will suggest an approach to the diagnosis of these disorders and provide an update on new therapies.

---

### Phenotype-genotype correlation in X-linked Charcot-Marie-Tooth disease: a French cohort study [^117EBLC2]. European Journal of Neurology (2025). Medium credibility.

Mutation types and clinical correlations

Apart from the 73 missense variants reported in this cohort, two nonsense (affecting 28 patients from 15 families) and six frameshift variants (affecting nine patients from seven families) were also found. Moreover, we identified five variants in the non‐coding regions such as the 5'UTR (affecting eight patients from five families) and one complete coding sequence deletion affecting a single patient (c.1_852del).

On statistical analysis, no significant differences were observed in the clinical and neurophysiological parameters among these different types of mutations (Table 2).

TABLE 2
Phenotype of variants causing X‐linked Charcot‐Marie‐Tooth disease, stratified by type of mutation.

Subgroup analysis

For a more focused analysis, we grouped nonsense variants, frameshift variants and the complete coding sequence deletion, as these should cause loss of function. This subgroup was then compared with the missense variants alone. Again, there were no statistically significant differences in the clinical and neurophysiological parameters between these two groups.

Case Study: Complete deletion

A 27‐year‐old male patient presented with a complete deletion (c.1_852del) in the GJB1 gene. His CMTES was 15 (breakdown: 3 + 1 + 1 + 3 + 4 + 2 + 1) and his ONLS was 3. The patient's symptoms characterized by muscle cramps appeared at age 20 years. Although he used orthoses, he did not require any walking assistance and had not undergone orthopedic surgery on his lower limbs. While the patient displayed tremor in the upper limbs, there were no signs of deafness, scoliosis, or stroke‐like symptoms. His median nerve MCV was 27 m/s and his ulnar nerve MCV was 33 m/s.

Comparatively, his clinical profile did not significantly differ from 16 male patients with missense variants, aged between 22 and 32 years. These findings indicate a lack of significant correlation between the type of mutation and clinical presentation, adding a layer of complexity to our understanding of genotype–phenotype relationships in neuromuscular diseases involving connexin 32 mutations. This could be valuable for future studies aiming to elucidate the underlying mechanisms of variability in clinical outcomes among patients.

---

### Hereditary sensory neuropathies [^115R87TT]. Current Opinion in Neurology (2004). Low credibility.

Purpose Of Review

The hereditary sensory neuropathies, also known as the hereditary sensory and autonomic neuropathies, are a clinically and genetically heterogeneous group of disorders. As they are not as common as Charcot-Marie-Tooth disease, they do not receive the same level of attention, but there have been major advances in the identification of the causative genes in the past decade. Certain forms of hereditary sensory and autonomic neuropathy, especially hereditary sensory and autonomic neuropathy type I, which has minimal autonomic involvement and is more accurately termed hereditary sensory neuropathy type I, can present in a very similar fashion to certain forms of Charcot-Marie-Tooth disease (Charcot-Marie-Tooth type 2B, see below), and therefore it is important that clinicians who regularly manage patients with neuropathy are familiar with the latest developments in the hereditary sensory and autonomic neuropathies. This review will concentrate on the recent genetic advances in hereditary sensory and autonomic neuropathy, and especially on those forms that overlap clinically with Charcot-Marie-Tooth disease, hence the title of the review 'Hereditary sensory neuropathies' rather than hereditary sensory and autonomic neuropathies.

---

### Vincristine sulfate [^115EbnSn]. FDA (2024). Medium credibility.

CONTRAINDICATIONS

Patients with the demyelinating form of Charcot–Marie–Tooth syndrome should not be given Vincristine Sulfate Injection. Careful attention should be given to those conditions listed under WARNINGS and PRECAUTIONS.

---

### Intermediate Charcot-Marie-Tooth disease due to a novel trp101Stop myelin protein zero mutation associated with debilitating neuropathic pain [^111pU7mN]. Pain (2012). Low credibility.

We report an English kindred affected across 4 generations with a hereditary neuropathy associated with debilitating neuropathic pain as the main clinical feature. The principal finding on clinical examination was sensory loss, and there was variable motor dysfunction. Electrophysiological studies revealed mild features of demyelination with median conduction velocity in the intermediate range. There was an autosomal-dominant pattern of inheritance, and genetic testing revealed a novel heterozygous Trp101X mutation in exon 3 coding for a portion of the extracellular domain of myelin protein zero. This is predicted to lead to premature termination of translation. Myelin protein zero is a key structural component of compact myelin, and over 100 mutations in this protein have been reported, which can give rise to neuropathies with either axonal, demyelinating, or intermediate features encompassing a wide range of severity. Chronic pain is an increasingly recognised sequela of certain hereditary neuropathies and may be musculoskeletal or neuropathic in origin. In this kindred, the neuropathy was relatively mild in severity, however, neuropathic pain was an important and disabling outcome.

---

### Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review) [^114WncaA]. Muscle & Nerve (2009). Medium credibility.

Charcot–Marie–Tooth (CMT) hereditary neuropathies — accuracy and scope of genetic testing are as follows: The CMT phenotype has been linked to 36 loci and mutations have been identified in 28 different genes, and currently available genetic testing is unequivocal for established pathogenic mutations, providing a specificity of 100% and high sensitivity. Data from six Class I, six Class II, and one Class III study indicate that genetic testing is useful for accurate classification, and in selected patients with the classic CMT phenotype with and without a family history of polyneuropathy the yield of genetic tests has been relatively high.

---

### Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2 [^112RPqt7]. Annals of Neurology (2016). Low credibility.

Figure 7
Rate of molecular diagnosis categorized according to inheritance modes. The upper table indicates the number of patients with molecular diagnoses by modes of inheritance in 726 patients. The pie chart below shows the rate of molecular diagnosis focused on the AR mode of inheritance. Only 17 of 77 (22%) patients received a molecular diagnosis in known CMT or IPN genes. Ten patients (13%) received a new molecular diagnosis, MME gene mutations. Rate of molecular diagnosis was increased to 35%. AR = autosomal‐recessive; CMT = Charcot–Marie–Tooth; IPN = inherited peripheral neuropathy.

In conclusion, for the first time, we identified MME as the most common causative gene for AR‐CMT using WES followed by the ESVD system with an overlap‐based strategy. Our genetic and immunohistochemical data strongly support the finding that the MME gene is a novel causative gene for AR‐CMT. All 10 patients with the MME mutation had a similar phenotype with a late‐onset axonal‐type motor and sensory neuropathy, but with no evidence of Alzheimer's disease, and we propose this new classification as AR‐CMT type 2T. Identification of the MME mutations responsible for AR‐CMT can improve the rate of molecular diagnosis, understanding of the molecular mechanisms of CMT, and establishment of effective therapeutic approaches.

---

### Cost of illness in Charcot-Marie-Tooth neuropathy: results from Germany [^115M7C3T]. Neurology (2019). Medium credibility.

Objective

To assess cost associated with the disease-specific need of patients diagnosed with Charcot-Marie-Tooth neuropathies (CMT) in Germany.

Methods

Patients with CMT were identified through the national patient registry and invited to complete a standardized questionnaire. The data collected include information about health care use, informal care, and other disease-related expenses as well as the working situation. Based on this information, we estimated the annual cost of CMT from the perspective of society.

Results

This study included 397 patients with a genetically confirmed CMT diagnosis. We estimated total annual cost of illness (COI) of $22,362 (95% CI $19,464-$25,723) per patient, of which 67.3% were direct costs. The highest single cost factor was informal care cost. For Germany, we extrapolated total cost of CMT of $735.0 million ($639.8 million-$845.5 million). Multivariate regression analysis showed that total annual cost increased with disease severity (Charcot-Marie-Tooth Neuropathy Score). Age, CMT subtype, comorbidities, body mass index, and employment status were also predictors of a change in cost (p < 0.05). Moreover, we found differences in total cost depending on marital status, subjectively evaluated impairments, dependence on other persons, care level, educational level, and disease duration.

Conclusions

CMT is associated with a substantial economic burden. For the first time, the COI of CMT has been assessed and will serve as important input to decision-making in health policy, especially regarding research and development of therapies. Moreover, our results indicate the importance of the patient-reported perception of disease severity related to the consumption of resources.

---

### Transient leukoencephalopathy associated with X-linked Charcot-Marie-Tooth disease [^1137mumC]. Journal of Child Neurology (2010). Low credibility.

X-linked hereditary demyelinating neuropathy (Charcot-Marie-Tooth 1X) accounts for 10% to 20% of all hereditary demyelinating neuropathies and is caused by mutations in the GJB1 gene, which codes for connexin 32. Connexin 32 is a gap junction protein widely expressed in Schwann cells as well as oligodendrocytes. Transient leukoencephalopathy has been reported in children and adults with Charcot-Marie-Tooth 1X. The case of a previously healthy 10-year-old boy who presented with fluctuating neurological deficits is reviewed. His brain magnetic resonance imaging scans showed abnormal restricted diffusion and mild hyperintense T2-weighted and fluid attenuation inversion recovery abnormalities in the splenium of the corpus callosum and the posterior cerebral white matter in a bilaterally symmetric distribution. A family history of Charcot-Marie-Tooth disease was revealed late in his presentation, and genetic testing identified a mutation in the GJB1 gene that has not previously been associated with central nervous system involvement.

---

### Removing the idiopathic from the chronic sensory neuropathies [^114xYEFy]. Brain (2021). Medium credibility.

Peripheral neuropathies are common. Estimated to affect around 2.4% of the general population, rising to 8% in those over the age of 55, neuropathies can cause significant morbidity, and can sometimes be fatal. Peripheral nerves consist of motor nerves that convey motor signals from the spinal cord to the peripheries, sensory nerves that convey sensory signals from the peripheries to the CNS, along with sympathetic and parasympathetic nerve fibres that together make up the autonomic nervous system. While neuropathies can be classified into acute and chronic forms, they can also present symmetrically or in an asymmetric manner. Moreover, using neurophysiological and pathological criteria, neuropathies are often classified into demyelinating or axonal forms, reflecting the principal site of pathology as the myelin-forming Schwann cell or the axon, respectively. Furthermore, neuropathies can be classified into those that are inherited, such as the Charcot-Marie-Tooth and related disorders, and those believed to be acquired. Of the latter group, the commonest risk factor associated with an acquired peripheral neuropathy seen in European populations is diabetes mellitus, while infectious and toxic causes remain prevalent worldwide. Nevertheless, despite careful and thorough investigation, it is estimated that between 20% and 40% of neuropathies that present to the clinic have no identifiable cause — hence the longstanding and common use of 'idiopathic' or 'cryptogenic' — and are now grouped together under the diagnostic label of 'chronic idiopathic axonal polyneuropathy' (CIAP).

The CIAPs mainly present with sensorimotor involvement (where both sensory and motor symptoms and signs exist), but a pure sensory neuropathy has also long been recognized, along with a rarer pure motor syndrome. Onset of symptoms is generally in the fifth decade and electrophysiological and histopathological studies are consistent with axonal degeneration. These neuropathies tend to deteriorate slowly and management is currently supportive and focused on symptoms. Previous observational studies aimed at identifying latent underlying risk factors and causes have been largely unsuccessful, hindering efforts to develop effective therapies.

In contrast, many other forms of neuropathy are treatable. While acquired inflammatory neuropathies are commonly managed with immunomodulation, the past decade has seen the development of novel yet effective therapies for previously untreatable inherited neuropathies. These treatments are the culmination of years of scientific investigation which began with the discovery of mutations in disease-associated genes in affected families, followed by the deciphering of molecular pathological mechanisms at the cellular level, leading finally to the identification of potential therapeutic pathways amenable to pharmacological targeting.

---

### Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants [^114GCczi]. Brain (2023). Medium credibility.

Charcot-Marie-Tooth disease (CMT) due to GJB1 variants (CMTX1) is the second most common form of CMT. It is an X-linked disorder characterized by progressive sensory and motor neuropathy with males affected more severely than females. Many reported GJB1 variants remain classified as variants of uncertain significance (VUS). In this large, international, multicentre study we prospectively collected demographic, clinical and genetic data on patients with CMT associated with GJB1 variants. Pathogenicity for each variant was defined using adapted American College of Medical Genetics criteria. Baseline and longitudinal analyses were conducted to study genotype-phenotype correlations, to calculate longitudinal change using the CMT Examination Score (CMTES), to compare males versus females, and pathogenic/likely pathogenic (P/LP) variants versus VUS. We present 387 patients from 295 families harbouring 154 variants in GJB1. Of these, 319 patients (82.4%) were deemed to have P/LP variants, 65 had VUS (16.8%) and three benign variants (0.8%; excluded from analysis); an increased proportion of patients with P/LP variants compared with using ClinVar's classification (74.6%). Male patients (166/319, 52.0%, P/LP only) were more severely affected at baseline. Baseline measures in patients with P/LP variants and VUS showed no significant differences, and regression analysis suggested the disease groups were near identical at baseline. Genotype-phenotype analysis suggested c.-17G > A produces the most severe phenotype of the five most common variants, and missense variants in the intracellular domain are less severe than other domains. Progression of disease was seen with increasing CMTES over time up to 8 years follow-up. Standard response mean (SRM), a measure of outcome responsiveness, peaked at 3 years with moderate responsiveness [change in CMTES (ΔCMTES) = 1.3 ± 2.6, P = 0.00016, SRM = 0.50]. Males and females progressed similarly up to 8 years, but baseline regression analysis suggested that over a longer period, females progress more slowly. Progression was most pronounced for mild phenotypes (CMTES = 0–7; 3-year ΔCMTES = 2.3 ± 2.5, P = 0.001, SRM = 0.90). Enhanced variant interpretation has yielded an increased proportion of GJB1 variants classified as P/LP and will aid future variant interpretation in this gene. Baseline and longitudinal analysis of this large cohort of CMTX1 patients describes the natural history of the disease including the rate of progression; CMTES showed moderate responsiveness for the whole group at 3 years and higher responsiveness for the mild group at 3, 4 and 5 years. These results have implications for patient selection for upcoming clinical trials.

---

### Clinical phenotype in X-linked Charcot-Marie-Tooth disease with an entire deletion of the connexin 32 coding sequence [^111Q44Dr]. Journal of the Neurological Sciences (2001). Low credibility.

To clarify the clinical phenotype and molecular mechanism in X-linked Charcot-Marie-Tooth disease (CMTX) patients with a deletion of the whole connexin 32 (Cx32) coding sequence, we studied a family with this deletion by electrophysiology, Southern blotting and quantitative PCR analyses. Two brothers with no copy of Cx32, 27 and 25 years old, showed steppage gait, moderate muscle atrophy and weakness, and mild sensory disturbance in the distal parts of the legs. The clinical phenotypes in these brothers were not different from those in patients with other types of severe Cx32 mutations. Their mother, with one copy of Cx32, showed very mild muscle weakness and sensory disturbance. An electrophysiological study showed a nonuniform demyelinating neuropathy with some aspects of an axonal-loss neuropathy. Sural nerve biopsy showed loss of myelinated fibers, many relatively thin myelin sheaths, clusters of small myelinated fibers, and some onion bulb formations. The present findings suggest that both a demyelinating process and an axonal involvement were present in the patients with total defect of Cx32 probably due to loss of the function mechanism of Cx32 as the underlying molecular mechanism, because a dominant negative effect theory is not applicable in these patients.

---

### Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants [^111ADJZR]. Brain (2023). Medium credibility.

Baseline characteristics of cohort overall and by variant class

Overall baseline data and comparison of baseline data by genetic variant class and by sex are shown in Table 2. For the whole cohort, mean age at recruitment was 40.6 ± 17.0 years and 53.4% (205/384) were male. Patients (74.5%, 284/381) had walking difficulty, 78.0% (288/369) had foot deformity, 20.9% (80/383) had foot surgery and 11.0% (41/372) had scoliosis, all in keeping with values previously published. Orthotics were required by 58.9% (225/382) and 12.5% (47/376) needed an assistive device to walk. Baseline CMTES and CMTNS were 9.7 ± 4.7 and 13.7 ± 6.2, respectively, again similar to previous studies when adjusted for age.

Table 2
Baseline characteristics of cohort overall, by variant classification and by sex

Demographic and clinical data were compared for pathogenic variants and VUS. Most patients had pathogenic variants (83.1%, 319/384) compared with VUS (16.9%, 65/384). Across all comparators there were no statistically significant differences between the two groups. Nearly identical mean values were seen for age at recruitment (40.6 ± 17.3 years, versus 40.3 ± 15.8 years), age of lower limb symptom onset (19.9 ± 14.3 years versus 20.9 ± 15.4 years), ulnar motor nerve conduction velocity (MNCV; 42.3 ± 8.7 m/s versus 41.9 ± 9.1 m/s), median MNCV (39.6 ± 9.3 m/s versus 39.2 ± 9.4 m/s), ulnar compound motor action potential (CMAP; 5.3 ± 2.9 mV versus 5.5 ± 3.6 mV), CMTES (9.6 ± 4.8 versus 10.0 ± 4.2) and CMTNS (13.6 ± 6.3 versus 13.8 ± 5.3) for pathogenic variants and VUS, respectively. Such tight concordance between the two groups suggests there is no difference between them in terms of demographic and clinical parameters and raises the possibility that the VUS may be pathogenic if more data were available on them.

---

### Development and validation of the Charcot-Marie-Tooth disease infant scale [^115Gm2rX]. Brain (2018). Low credibility.

Many genetic subtypes of Charcot-Marie-Tooth disease (CMT) show signs of symptomatic disease during the earliest years of life. This might be the ideal time to intervene before progression of clinical sequelae due to demyelination and axonal loss. In the absence of disease-specific clinical trial outcome measures for CMT during infancy and early childhood the aim of this study was to develop and validate a functional measure of disease severity, known as the Charcot-Marie-Tooth disease Infant Scale (CMTInfS). Development projects involved identification of a preliminary pool of 31 items representing the range of disability in affected patients aged 0–4 years from a systematic review of the literature, peer review by 12 expert clinicians and researchers in the field, design of a scoring algorithm and pilot testing in 22 participants. Subsequently, a series of validation projects were conducted based on 128 assessments of: 26 confirmed cases of inherited neuropathy (17 CMT1A, one CMT1B, one CMT1D, one CMT2C, one CMT2S, two CMT4C, one CMTX3, one Riboflavin Transporter Deficiency Type 2, and one unidentified mutation); seven 'at risk' cases and 95 unaffected healthy controls recruited through the NIH-funded Inherited Neuropathies Consortium. Validation projects included: Item, Factor and Rasch analysis, intra- and inter-rater reliability, discriminant ability and convergent validity with the CMT Pediatric Scale (CMTPedS) for children aged 3–4 years. Development and validation projects produced a psychometrically robust 15-item scale. Rasch analysis supported the viability of the CMTInfS as a unidimensional measure of disease severity and showed good overall model fit, no evidence of misfitting items or persons and was well targeted for affected children. The CMTInfS demonstrated high intra-rater reliability [intraclass correlation coefficient (ICC)3,1 0.999, 95% confidence interval 0.996–1.000) and inter-rater reliability (ICC2,1 0.997, 95% confidence interval 0.992–0.999). The CMTInfS was able to discriminate between the CMT group and controls (P = 0.006), and convergent validity demonstrated good agreement between CMTInfS and CMTPedS scores (r = 0.76, P = 0.01). The final version of the CMTInfS requires 20 min to administer and is a reliable and sensitive functional outcome measure for early onset CMT and related neuropathies.10.1093/brain/awy280_video1awy280media15970672819001.